JNJ


Line plots across dimensions of each concept
Tables

Table of contents



us-gaap:CommonStockSharesIssued

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareDiluted

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementBusinessSegments
us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:StatementBusinessSegments
us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:StatementGeographical
us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

us-gaap:Revenues

us-gaap:CostOfGoodsAndServicesSold

us-gaap:GrossProfit

us-gaap:SellingGeneralAndAdministrativeExpense
us-gaap:ConsolidationItems
us-gaap:OperatingIncomeLoss
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:InterestExpense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:IncomeTaxExpenseBenefit

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:Assets

us-gaap:Liabilities

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AccountsReceivableNetCurrent

us-gaap:InventoryNet

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:Goodwill
us-gaap:BusinessAcquisition
us-gaap:StatementBusinessSegments

us-gaap:IntangibleAssetsNetExcludingGoodwill
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsNet

us-gaap:OtherAssetsNoncurrent
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:LiabilitiesCurrent

us-gaap:AccountsPayableCurrent

us-gaap:AccruedIncomeTaxesCurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:TreasuryStockValue

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:DepreciationDepletionAndAmortization

us-gaap:IncreaseDecreaseInInventories

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquireInvestments

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:RepaymentsOfLongTermDebt

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:RepaymentsOfLongTermDebt

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:ShareBasedCompensation

us-gaap:UnrecognizedTaxBenefits
us-gaap:BalanceSheetLocation

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

jnj:CostOfGoodsSoldPercentToSales
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod

jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue

jnj:GrossProfitPercentToSales

jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales

jnj:IncomeTaxExpenseBenefitPercentToSales

jnj:InterestExpensePercentToSales

jnj:InvestmentIncomeInterestPercentToSales

jnj:NetIncomeAttributableToParentPercentToSales

jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax

jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax

jnj:OtherNonOperatingIncomeExpensePercentToSales

jnj:PercentageChangeInOperatingIncomeLoss
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

jnj:PercentageChangeInSalesByGeographicArea
us-gaap:StatementGeographical

jnj:PercentageChangeInSalesBySegmentOfBusiness

jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits

jnj:Proceedsfromcreditsupportagreements

jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales

jnj:ResearchAndDevelopmentInProcessPercentToSales

jnj:Restructuringchargepercenttosales

jnj:SellingGeneralAndAdministrativeExpensePercentToSales

jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:AdjustmentForAmortization

us-gaap:AmortizationOfIntangibleAssets

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:AssetImpairmentCharges

us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition, us-gaap:IncomeStatementLocation

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CommonStockDividendsPerShareCashPaid

us-gaap:DeferredIncomeTaxExpenseBenefit
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanInterestCost
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanServiceCost
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:DerivativeGainLossOnDerivativeNet
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred

us-gaap:DividendsCommonStockCash
us-gaap:StatementEquityComponents

us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:EquityFairValueAdjustment

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges

us-gaap:GoodwillAcquiredDuringPeriod
us-gaap:StatementBusinessSegments

us-gaap:GoodwillOtherIncreaseDecrease
us-gaap:StatementBusinessSegments

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

us-gaap:IncreaseDecreaseInAccountsReceivable

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

us-gaap:InvestmentIncomeInterest
us-gaap:StatementBusinessSegments
us-gaap:LitigationSettlementExpense
us-gaap:LitigationCase, us-gaap:LitigationStatus
us-gaap:LossContingencyDamagesAwardedValue
us-gaap:LitigationStatus

us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1

us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1

us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax

us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
us-gaap:DerivativeInstrumentRisk

us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

us-gaap:OtherComprehensiveIncomeLossNetOfTax
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

us-gaap:PaymentsForProceedsFromOtherInvestingActivities
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:PaymentsForRestructuring
us-gaap:RestructuringPlan

us-gaap:PaymentsOfOrdinaryDividends

us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
us-gaap:BusinessAcquisition
us-gaap:RetirementPlanSponsorLocation
us-gaap:PensionContributions

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities

us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments

us-gaap:ProceedsFromSaleOfProductiveAssets

us-gaap:ProceedsFromShortTermDebt

us-gaap:ProvisionForDoubtfulAccounts

us-gaap:RepaymentsOfShortTermDebt

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

us-gaap:ResearchAndDevelopmentInProcess

us-gaap:RestructuringCharges
us-gaap:IncomeStatementLocation, us-gaap:RestructuringPlan
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringPlan
us-gaap:StatementBusinessSegments
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringReserveSettledWithoutCash2
us-gaap:RestructuringPlan

us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
us-gaap:StatementEquityComponents

us-gaap:TreasuryStockValueAcquiredCostMethod
us-gaap:StatementEquityComponents
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:UnrealizedGainLossOnSecurities

jnj:AccruedRebatesReturnsAndPromotions
us-gaap:ProductOrService
jnj:ProductLiabilityContingencyNumberOfClaimant

us-gaap:AccruedIncomeTaxesNoncurrent

us-gaap:AccruedLiabilitiesCurrent

us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent

us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:BusinessCombinationContingentConsiderationLiability
us-gaap:BalanceSheetLocation
us-gaap:BalanceSheetLocation, us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

us-gaap:DeferredIncomeTaxAssetsNet

us-gaap:DeferredIncomeTaxLiabilitiesNet

us-gaap:DerivativeAssetFairValueGrossLiability

us-gaap:DerivativeAssets

us-gaap:DerivativeFairValueOfDerivativeAsset

us-gaap:DerivativeFairValueOfDerivativeLiability

us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:DerivativeLiabilities

us-gaap:DerivativeLiabilityFairValueGrossAsset
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeNotionalAmount

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent

us-gaap:EquitySecuritiesFvNi
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsGross
us-gaap:DerivativeInstrumentRisk
us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:DerivativeInstrumentRisk
us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecurities
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecuritiesFairValue
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
us-gaap:BusinessAcquisition, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:InventoryFinishedGoodsNetOfReserves

us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves

us-gaap:InventoryWorkInProcessNetOfReserves

us-gaap:MarketableSecuritiesCurrent
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:MarketableSecuritiesNoncurrent
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringReserve
us-gaap:RestructuringPlan

us-gaap:ShortTermBorrowings
us-gaap:FairValueByMeasurementBasis

us-gaap:TreasuryStockShares

Tables

  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:CommonStockSharesIssued ▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁█▁▁▁▁▁31193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119312031193119311931193119NANANA3119NANANA
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding 2671NA266926912698NA272727212731NA273727412754NA278527942795NA280728122826NA286428742874NA288128932858NA281827982774NA277827812772NA278627962797NANANANA
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic 2633NA263526522660NA268326822682NA268426912706NA273127452757NA276827722782NA281428262826NA281828092790NA275727472736NA273727402738NA275127562755NANANANA
us-gaap:EarningsPerShareBasic █▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇2.21.520.672.111.411.141.471.471.63-3.991.41.421.631.411.561.461.561.161.211.631.550.91.691.531.671.251.061.361.250.931.080.511.430.081.171.011.270.711.241.251.640.81.211.161.27
us-gaap:EarningsPerShareDiluted █▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇2.171.50.662.081.391.121.441.451.6-3.991.371.41.611.381.531.431.541.151.21.611.530.891.661.511.641.231.041.331.220.911.050.51.410.081.151.01.250.71.231.231.620.791.21.151.26
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax ████▇▇▇█▇▇▇▆▄▅▄▅▄▄▄▄▄▅▅▆▅▅▄▄▄▄▃▃▂▃▂▃▂▂▁▁▂▃▁▁▁206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments jnj:Consumer▄▃▃▃▂▃▂▃▂▃▂▃▁▃▁▂▁▂▂▃▂▄▄▅▃▅▄▄▄▄▄▄▄▄▅▅▄▄▃▄▅█▆▅▄362535673469354433183536341535043398354033563478322834323261341931953320331434833390360635893744355737533611365836753652358136193595366837403793368236103567364737664249398938543711
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments jnj:MedicalDevices▁▆▄▅▅▆▅█▇█▅▆▃5932663263836489645966686587697267676974659967266293NA615964096109NA609463586258NA657172427060NANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments jnj:Pharmaceutical█▇█▇▇▇▇▇▆▆▆▅▅▅▅▅▄▄▄▄▄▄▅▅▄▃▃▃▃▃▂▂▂▂▂▂▂▂▁▁▁▂▁▁▂11134105481087710529102441019010346103549844968196958635824582328400865481788064769479467726799983078509749872967036702567686525640262916133609459826233605957105495555356385993524954985780
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments,us-gaap:Subsegments jnj:MedicalDevices,jnj:Surgery▁▆▄▅▅█▅▇▆█▅▅▃2100244223112353239525872376251524232558234623842271NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments,us-gaap:Subsegments jnj:Pharmaceutical,jnj:Immunology▇▆█▆▄▅▅▅▂▂▄▁▁3638352237113466325133423398333830423086326929592930NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments,us-gaap:Subsegments jnj:Pharmaceutical,jnj:Oncology█▇▇▆▆▅▆▅▅▃▂▂▁3013271627612697251824892588245623112039189817271594NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical country:US███▆▅▇▇▇▄▆▆▃▁10699107741079110403101291062910664106409951104691029097269378NA938195729321NA8791891186928604884291328204NA792579468025NA779173607219NA686874477608NA7131NANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical jnj:AsiaPacificAfrica3663NA398939713780NA371838403694NA348333823076NA321132782983NA3046322430033308335934443331NA333033543216NA34543222NANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical srt:Europe4827NA446147334609NA441648104797NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical us-gaap:NonUs▇▇▇█▇▆▆█▇▆▅▄▁9992997399381015998929765968410190100589726936091138388NA8439NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical,us-gaap:StatementBusinessSegments country:US,jnj:MedicalDevices▁▆▄▅▅▇▇█▆289831353057308331093214319732653161NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical,us-gaap:StatementBusinessSegments country:US,jnj:Pharmaceutical▆▇█▄▃▅▆▅▁606161696340578355825936609758995354NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical,us-gaap:StatementBusinessSegments us-gaap:NonUs,jnj:MedicalDevices▁▆▄▅▄▅▅█▇303434973326340633503454339037073606NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical,us-gaap:StatementBusinessSegments us-gaap:NonUs,jnj:Pharmaceutical█▂▃▅▅▁▁▃▃507343794537474646624254424944554490NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical,us-gaap:StatementBusinessSegments,us-gaap:Subsegments country:US,jnj:Pharmaceutical,jnj:Immunology▆▇█▆▃▅▆▅▁241025172582237921632356240023172000NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:Revenues ████▇▇▇█▇▇▇▆▄▅▄▅▄▄▄▄▄▅▅▆▅▅▄▄▄▄▃▃▂▃▂▃▂▂▁▁▂▃▁▁▁206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
us-gaap:CostOfGoodsAndServicesSold ▆▇▄▅▁▅▁▅▁█▅70627134686769406615696165896927661472596925NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:GrossProfit ▇▇█▇▇▇██▇▆▆▆▅▅▅▆▅▄▄▅▄▅▆▇▆▅▅▅▄▃▃▃▃▂▂▃▃▁▁▂▂▃▂▂▂136291361313862136221340613433137591390313395129521274813016123801257212334131461215312138118781243012092124011306813456126601240012231123881195111555114551133211224109171093311425113951060410388107001110311239106471078910775
us-gaap:SellingGeneralAndAdministrativeExpense ▄█▄▅▄█▅▆▄█▅▄▁5203603953745546521959915543574352636025539652624737NA477251764688NA5081538448475822546854815183NA531453765223NA522849655015NA524052155056NA470947564779NANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems us-gaap:CorporateNonSegment120NA176231147NA230303312NA328316247NA233293192NA256282252NA243249NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems us-gaap:OperatingSegments6629NA182372724569NA465352765793NA511850645822NA551451975486NA437860235827NA70535875NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:Consumer770NA653406741NA510829548NA878658596NA679571566NA811317644NA407703NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:MedicalDevices2025NA139231891497NA12677961579NA13839921563NA15269391576NA83515842221NA33991703NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:Pharmaceutical3834NA-22236772331NA287636513666NA285734143663NA330936873344NA273241222962NA32473469NANANANANANANANANANANANANANANANANANANANANA
us-gaap:InterestExpense ▁▃▂▃▃▇▇▇██▇▇▆25854883102250243253259274229227204NA192190160NA123131138139130128136NA105118125NA135143147NA134129125NA108101108NANANANA
us-gaap:OtherNonoperatingIncomeExpense ▇▆▁█▆▅▆▆▆▆▆▅▆679-16-4214168322-978-3-364-609236-588160NA54-55739NA-420931348-9631345-226-86NA-943-172-515NA90-2008611NA308-20613NA292-181594NANANANA
us-gaap:IncomeTaxExpenseBenefit ▁▁▁▂▁▁▁▂▂█▂▂▂713208-106143467380489101911141327310269211153NA10099071002NA7641225125518220611300697NA685960764NA9666271135NA9096461034NA8027711754NANANANA
us-gaap:ComprehensiveIncomeNetOfTax 5444NA118961553454NA406417855190NA425151154801NA426436815066NA255157621742-2819237439644942NA444637122618NA4247-2565002NA1324NANANANANANANANANANA
us-gaap:NetIncomeLoss █▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▇█▇█▇▇▇▇▇▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇579640101753560737493042393439544367-107133764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings█▅▁█▄▃▅▅▆579640101753560737493042393439544367NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:Assets ████▇▇█████▇▆▆▆▆▅▅▅▅▄▅▅▅▅▅▄▄▃▃▃▃▃▂▂▂▂▁155017157728155521155117150027152954155703155365156625157303155658152807144918141208140369139814136231133411133266132036128590131119132097135200133330132683126933124325121536121347118951115750116194113644111821112114108150102908NANANA94682NANANA
us-gaap:Liabilities ▇██▇▇▇▇▇▇█▆▆▅▄▄▄▃▃▃▃▃▃▂▂▂▃▂▂▂▂▂▂▂▂▂▁▁▁9372398257973119433291072932029107792476933709714381679808857457770790676006734163584622616171260905607126136755506571525674858630571295466054681565215519055316548285656450294499824828746329NANANA44094NANANA
us-gaap:LiabilitiesAndStockholdersEquity ████▇▇█████▇▆▆▆▆▅▅▅▅▄▅▅▅▅▅▄▄▃▃▃▃▃▂▂▂▂▁155017157728155521155117150027152954155703155365156625157303155658152807144918141208140369139814136231133411133266132036128590131119132097135200133330132683126933124325121536121347118951115750116194113644111821112114108150102908NANANA94682NANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:AssetsCurrent ▂▃▂▂▂▃▃▃▂▂▂▁▇█▇█▇▆▇▇▆▆▆▆▆▅▄▄▃▃▃▂▆▅▅▅▄▃4422645274443334179941987460334719445438427684308841829387896334765032633196629162738602106349461001581925931159973601195736956407521765127347228461164479141615570075431653443526734922147307NANANA39541NANANA
us-gaap:CashAndCashEquivalentsAtCarryingValue ▃▃▃▂▂▄▃▃▂▄▃▂▅▄▄▄▂▂▂▁▁▂▂▂▄▅▃▃▃▃▃▂█▆▃▃▅▄▂▂▂▃155301730516249143761473418107160561756914639178241572112598209091897218205186401386113732136391063911988145231381814236197222092717204173071485514911154861404230267245421561714974223561935514338127131374315810NANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity us-gaap:AvailableforsaleSecurities▄▂▂▁▄██4275311032091865417181547847NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity us-gaap:HeldtomaturitySecurities▅█▇▆▄▃▁112551419513040125111056399538209NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity,us-gaap:InvestmentType us-gaap:AvailableforsaleSecurities,us-gaap:USTreasuryAndGovernment▄▂▃▁▄██4260309531951845414381447835NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity,us-gaap:InvestmentType us-gaap:HeldtomaturitySecurities,us-gaap:Cash▁▄▅▄█▄▃2499263726672615277826192575NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity,us-gaap:InvestmentType us-gaap:HeldtomaturitySecurities,us-gaap:MoneyMarketFunds▄▅▁▁█▆▂2424286414811368419533971763NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity,us-gaap:InvestmentType us-gaap:HeldtomaturitySecurities,us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase3965NA618270142068NA2260NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:AccountsReceivableNetCurrent █▇██▇▇▇▇▇▆▆▆▄▄▄▄▃▂▃▄▃▃▄▄▄▄▄▄▃▃▃▃▃▂▂▃▂▁148741448114801146531411514098140481411114166134901315513283123001169911798120621140610734113661196811533109851161512257121161171312027116141151511309111751099210982105811055210982108619774NANANA9646NANANA
us-gaap:InventoryNet ▇▇▇▇▇▆▆▇▇▆██▇▅▆▆▆▅▆▆▅▆▆▅▅▅▅▅▅▄▅▅▃▂▃▃▂▁88689020917392639086859986788810901487659521969988788144848885238170805382068298808581848419815580097878812478227691749578097697680062856428641362005378NANANA5180NANANA
us-gaap:PrepaidExpenseAndOtherAssetsCurrent ▂▂▁▂▂▃▄▂▃▂▄▄▃▅▂▅▅▄▄▄▇▆▄███▅▆▅▄▃▄▃▃▄▅235823922220241125992699289625692641253729222954282632822600312233073047301030583731348631073982393240033312342532603084278928942683263330563290NA2273NANANANANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:PropertyPlantAndEquipmentGross ████▇▇▇▇▇▇▇▆▅▅▅▅▅▄▄▄▄▄▄▅▄▅▄▄▃▃▃▃▂▂▂▂▂▁4324743332426254290542262418514152041293419964146640928400753869637773383733777937430366483639736112354033668536448369473624837133364323540134695346543408233297325503182931736324353180530426NANANA29251NANANA
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment █████▇▇▇▇▇▇▆▆▅▅▅▅▄▄▄▄▄▄▄▄▄▄▄▃▃▃▂▂▂▂▂▂▁2584625674255772565725262248162489124661249562446124300236172250521861222782180721466207432084620529200392055920644207922025220423203051960718974185571823717675177261709017101174611672115873NANANA14492NANANA
us-gaap:PropertyPlantAndEquipmentNet ▇█▇▇▇▇▆▆▇▇▆▅▅▄▄▄▄▄▃▃▃▅▄▅▄▆▅▄▄▄▄▃▂▁▁▂▂▁1740117658170481724817000170351662916632170401700516628164581619115912160951597215964159051555115583153641612615804161551599616710161271579415721160971584515622148241473914635149741508414553NANANA14759NANANA
us-gaap:Goodwill ████▇▇▇▇▇▇▇▇▅▄▄▄▃▃▃▃▃▃▃▄▄▄▄▄▄▄▃▃▁▁▁▁▁▁3347133639332913366131450304533070230346311493190631308312342484422805231712210421848216292127921493213452183221636219892217822798228522233722349224242177721412163391613816049162431612615294NANANA14862NANANA
 us-gaap:Goodwill us-gaap:StatementBusinessSegments jnj:Consumer▇█▇██▅▅▅▆▅▅▅▄▄▅▂▂▁▁▂▁▂▃▄▄▅▅▄▄▅▄▄▄▄▄▄951397369595981797308670874085788899887588488630834482638575751574127240720874067274767579848324851285318617841184778519845981798470829883358464NA8144NANANA8074NANANA
 us-gaap:Goodwill us-gaap:StatementBusinessSegments jnj:MedicalDevices████▄▄▄▄▄▆▆▆▅▂▂▂▁▁▁▁▁▁14884147341471914740127321272012850127261299413922137741371413646117021170211699115241150011454114681145911531NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:Goodwill us-gaap:StatementBusinessSegments jnj:Pharmaceutical██████████▇█▂▂▂▂▂▂▂▂▂▂▁▁▁▁▁▁▁▁▁▁▁▁▁▁907491698977910489889063911290429256910986868890285428402894289029122889261726192612262620922059206520682054177817621792176817421742172117681815NA1225NANANA1244NANANA
us-gaap:IntangibleAssetsNetExcludingGoodwill ▇▇▇▇▇▇▇▇████▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▁▁▁▁▁▁4733847643478464933246898476114863750056523655322854569549422946626876276422569425840257642598827017270252722226304271222764327947284672770428009287522879029199181571813818225183781868716716NANANA16323NANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass jnj:PatentsAndTrademarks▆▆▆▇▇▇▇▇████▂▂▂▁▁▁▁▁▁▁▁▁▁▁▁▁▁▂▂▂▁▁2235723480239562508225415254102640126556283862920429947302586085544557983659347235543611411141994374437746174899501851645231532654745557558250084971NANANANANANANANANANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass us-gaap:OtherIntangibleAssets▆▆▇▇▇▇▇▇▇▇▇▇▇▅▆▆▆▆▆▆▆▇▇▇▇███████▁▁123561259412725129881318013011130081314413393127411294412995129121110011419115571178611767121021250712516127431318113781139761415514165141291429814725147551466751515284NANANANANANANANANANANA
us-gaap:OtherAssetsNoncurrent ▆▇▆▆▆▄▄▄▅▅▅▆▅▄▄▄▄▄▃▃▃▂▅██▅▁▁▃▃▃▃▄▃▄▄▃▄50425695530754305159418244654421451849715021527346904435424539774163441338043855360532325033643564594949271524773723341735213891395637733905419337053942NANANA3690NANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByAssetClass,us-gaap:OtherInvestmentNotReadilyMarketable us-gaap:EquitySecurities,jnj:EquityInvestmentswithReadilyDeterminableValue▄█▅▆▅▁▃▃▃8261148863963830511697697731NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByAssetClass,us-gaap:OtherInvestmentNotReadilyMarketable us-gaap:EquitySecurities,jnj:EquityInvestmentswithoutReadilyDeterminableValue▇█▇▆▇▆▄▄▁694712699677698681639624573NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:LiabilitiesCurrent ▇██▆▅▆▄▄▄▅▆▅▃▃▂▁▂▄▃▃▂▃▂▃▂▃▃▂▂▃▂▂▁▂▁▁▂▂3368935964351623135329111312302743727488270813053731806288722511926287232302153622134277472526024512238362508522982243592384025675258352376722524242622393523848211982281121686209852401123072NANANA21731NANANA
us-gaap:AccountsPayableCurrent ▆█▆▅▅▆▅▄▄▆▄▃▃▅▃▃▃▄▃▃▄▆▄▃▃▃▃▂▂▃▂▁▁▂▂▂▂▂74118544749169126923753770006516644373106390613560826918597160615965666859286140671976336603619361136266605556875372583153445145508557255730568957015623NANANA5541NANANA
us-gaap:AccruedIncomeTaxesCurrent ▆▇█▅▃▂▃▂▅▆▃▂▃▃▂▂▃▂▃▂▄▁▅▃▂▂▅▃▃▃▄▄▂▂▄▂▃▁19302266250517011025818109692815591854118375911339717986909687509319161243500153510558627701711956117810641502125991485413368081007578NANANA442NANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:LongTermDebtNoncurrent ▆▇▇▇▇▇████▇▇▇▅▆▆▅▂▃▃▃▃▂▂▂▂▁▁▂▂▂▂▂▂▂▂▁▁253932649426919276992766027684294802940529837306752667527363270152244223546245352023312857140731408514938151221315213303133431332897489643113631148911428115251301012969130311368092559156NANANA8223NANANA
us-gaap:OtherLiabilitiesNoncurrent ▇██▆▄▄▄▅▄▄▄▆▅▅▅▆▅▆▅▄▄▃▃▂▂▃▄▄▃▄▅▅▆▇▂▂▂▁10944117341138110102892885898538928188769017910210117952695369414100629749102419303897386048034775873737271785488958569819785529207948710538106317473722770016567NANANA5947NANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ▃▂▂▂▂▂▄▃▃▂▇▆▅▆▆▆▆▆▆▆▅▅███▇▅▅▄▄▃▂▃▁▃▃▂▁6129459471582106078558955597526462662889632556016073979719227034170418727697247372647711507155471131678786975276591780487658274053698046966566855648266376160434613665708061527621325986356579NANANA50588NANANA
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:RetainedEarnings█▇▆▆▄▄▅▄▃▁112901110659109242109809106650106216107617106123104339101793NANANA110551NANANA103879NANANA97245NANANA89493NANANA85992NANANA81251NANANA77773NANANA70306NANANA
us-gaap:RetainedEarningsAccumulatedDeficit █▇▇▇▆▆▇▆▆▆██▇▇▇▆▆▆▆▅▅▅▅▄▄▃▃▃▃▃▂▂▂▂▂▂▁▁112901110659109242109809106650106216107617106123104339101793114805113208111643110551108860106738104990103879102748101352986569724596560937459138789493877038944987242859928488083530831038125182634808367951577773NANANA70306NANANA
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▁▁▁▂▁▁▂▂▃▂▃▂▂▂▃▃▃▂▃▃▂▄▆▇▇▇▆▅▅▆▆▆▆▆▇██▇-16243-15891-15533-14969-15517-15222-14647-14777-12608-13199-12747-13234-14522-14901-12715-12707-12391-13165-12861-12054-13300-10722-5382-3007-2645-2860-5346-6810-6689-5810-4925-6204-4540-5632-3068-1192-2020-3531NANANA-3058NANANA
us-gaap:TreasuryStockValue ████▇▇▆▆▆▆▆▆▅▅▄▄▃▃▃▃▃▂▂▁▁▁▁▁▁▂▂▂▃▃▃▃▃▃3848438417386193717535298343623146431577315963155431199311722990028352264962467823072226842145321287205981989117707158101528015700156731609416818184761931420012203172165921159206322075220783NANANA19780NANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInOperatingActivities ▁▆█▅▁▆▆3358639875275948354362446272NA36066105NANA2913NANANA1763NA6125520028724365465455293923NANANA2277NANANA2795NANANA2316NANANA3690NANANANA
us-gaap:NetCashProvidedByUsedInInvestingActivities ▅▄▄▄▄█▁-581-1344-1645-1788-14172228-4269NA-925-505NANA-936NANANA-1537NA-1001-3554-1789-2922735-8092-2026NANANA-1403NANANA4056NANANA1440NANANA-1882NANANANA
us-gaap:NetCashProvidedByUsedInFinancingActivities ▆▇▇▅▃▁█-4315-4072-3893-4534-5516-6389-3477NA-5970-3537NANA-150NANANA-178NA-1825-2503-3227-619-5716-2868-3057NANANA-777NANANA-1183NANANA-825NANANA-3822NANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInOperatingActivities ▁▆█▅▁▆▆3358639875275948354362446272NA36066105NANA2913NANANA1763NA6125520028724365465455293923NANANA2277NANANA2795NANANA2316NANANA3690NANANANA
us-gaap:NetIncomeLoss █▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▇█▇█▇▇▇▇▇▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇579640101753560737493042393439544367-107133764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings█▅▁█▄▃▅▅▆579640101753560737493042393439544367NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DepreciationDepletionAndAmortization ▄█▂▁▅▃▃1747181617271705176117351731NA17461869NANA912NANANA891NA9298898959919399521013NANANA1036NANANA773NANANA755NANANA734NANANANA
us-gaap:IncreaseDecreaseInInventories ▅▁▃▄█▁▇159-147154369-133286NA322-774NANA368NANANA190NA1822612762249393512NANANA288NANANA449NANANA452NANANA193NANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInInvestingActivities ▅▄▄▄▄█▁-581-1344-1645-1788-14172228-4269NA-925-505NANA-936NANANA-1537NA-1001-3554-1789-2922735-8092-2026NANANA-1403NANANA4056NANANA1440NANANA-1882NANANANA
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ▁▇▂▃▁█▃62512607458376561318819NA6581240NANA560NANANA639NA7897655431496751837630NANANA586NANANA502NANANA436NANANA397NANANANA
us-gaap:PaymentsToAcquireInvestments ▅▂▂▁▁▃█20641236116778773014713204NA548355NANA4550NANANA10062NA795313651716291298432119255427NANANA3551NANANA2398NANANA1036NANANA3246NANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInFinancingActivities ▆▇▇▅▃▁█-4315-4072-3893-4534-5516-6389-3477NA-5970-3537NANA-150NANANA-178NA-1825-2503-3227-619-5716-2868-3057NANANA-777NANANA-1183NANANA-825NANANA-3822NANANANA
us-gaap:RepaymentsOfLongTermDebt ▁█▁▁▅▃▄111815331002645901NA8753NANA2NANANA14NA65165710175621NANANA1NANANA30NANANA3NANANA8NANANANA
us-gaap:PaymentsForRepurchaseOfCommonStock ▄▁▃▅▅█▁17114261628248622063808471NA1444815NANA3342NANANA2389NA3008962198274324151192774NANANA0NANANA67NANANA435NANANA383NANANANA
  2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:RepaymentsOfLongTermDebt ▁█▁▁▅▃▄111815331002645901NA8753NANA2NANANA14NA65165710175621NANANA1NANANA30NANANA3NANANA8NANANANA

Common Stock Value

Common Stock Par Or Stated Value Per Share

Common Stock Shares Issued

us-gaap:CommonStockSharesIssued



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value3119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931203119311931193119311931193119
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Common Stock Shares Authorized

Weighted Average Number Of Diluted Shares Outstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value2671266926912698272727212731273727412754278527942795280728122826286428742874288128932858281827982774277827812772278627962797
Percentage of WeightedAverageNumberOfDilutedSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Shares Outstanding Basic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value2633263526522660268326822682268426912706273127452757276827722782281428262826281828092790275727472736273727402738275127562755
Percentage of WeightedAverageNumberOfSharesOutstandingBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic

us-gaap:EarningsPerShareBasic



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value2.21.520.672.111.411.141.471.471.63-3.991.41.421.631.411.561.461.561.161.211.631.550.91.691.531.671.251.061.361.250.931.080.511.430.081.171.011.270.711.241.251.640.81.211.161.27
Percentage of EarningsPerShareBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Diluted

us-gaap:EarningsPerShareDiluted



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value2.171.50.662.081.391.121.441.451.6-3.991.371.41.611.381.531.431.541.151.21.611.530.891.661.511.641.231.041.331.220.911.050.51.410.081.151.01.250.71.231.231.620.791.21.151.26
Percentage of EarningsPerShareDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Revenue From Contract With Customer Excluding Assessed Tax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProductOrService, us-gaap:StatementBusinessSegments

jnj:BabyCare, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value361421417443394473472456457490477494455
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.72.02.02.22.02.32.32.22.32.42.42.62.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.72.02.02.22.02.32.32.22.32.42.42.62.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value111711501151120210901111107811091084111010331076981
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.45.55.65.85.45.45.35.35.45.55.35.75.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.45.55.65.85.45.45.35.35.45.55.35.75.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1348119510981064108711481048106610721105100210061013
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.55.85.35.25.45.65.25.15.45.55.15.35.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.55.85.35.25.45.65.25.15.45.55.15.35.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value395393379389367399384393379393382394362
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.91.81.91.82.01.91.91.91.91.92.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.91.81.91.82.01.91.91.91.91.92.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value232253255253225257269280243262270276242
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.21.21.11.31.31.31.21.31.41.51.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.21.21.11.31.31.31.21.31.41.51.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value171155168193155148164200163180192232175
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.80.90.80.70.81.00.80.91.01.21.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.80.90.80.70.81.00.80.91.01.21.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:ADVANCED, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value948107610101029980105597610059661023923933877
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.65.24.95.04.95.24.84.84.85.14.75.04.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.65.24.95.04.95.24.84.84.85.14.75.04.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value171152193137214150157183173203198181209
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.90.71.10.70.80.90.91.01.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.90.71.10.70.80.90.91.01.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value814833893842824816835844807800800753
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.94.04.34.14.14.04.14.14.04.04.14.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.94.04.34.14.14.04.14.14.04.04.14.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:DARZALEX, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value937830765774629584498511432371317299255
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.54.03.73.83.12.92.42.52.21.81.61.61.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.54.03.73.83.12.92.42.52.21.81.61.61.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value224222218210211193202211210192194179149
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.01.10.91.01.01.01.01.01.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.01.10.91.01.01.01.01.01.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ERLEADA, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-03-31
Value14361
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA jnj:Pharmaceutical jnj:Oncology100.0100.0

jnj:GENERAL, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1153117111011119108911811080116911271170110511141074
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.65.65.35.45.45.85.35.65.65.85.65.96.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.65.65.35.45.45.85.35.65.65.85.65.96.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value337377336364361365330360363364328350352
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.81.61.81.81.81.61.71.81.81.71.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.81.61.81.81.81.61.71.81.81.71.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1031875921831784703705620587522512450409
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.04.24.44.03.93.43.53.02.92.62.62.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.04.24.44.03.93.43.53.02.92.62.62.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value883871851818790763749720696693643629604
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.34.24.14.03.93.73.73.53.53.43.33.33.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.34.24.14.03.93.73.73.53.53.43.33.33.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value175177179177202228190215248267265295284
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.90.90.91.01.10.91.01.21.31.31.61.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.90.90.91.01.10.91.01.21.31.31.61.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value343395344372369392341382387397343385398
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.91.71.81.81.91.71.81.92.01.72.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.91.71.81.81.91.71.81.92.01.72.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value389326347348306323310311271269259450
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.61.71.71.51.61.51.51.41.31.30.20.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.61.71.71.51.61.51.51.41.31.30.20.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:OTHERNEUROSCIENCE, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value435383384401446409409437494431463450477
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.81.92.02.22.02.02.12.52.12.42.42.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.81.92.02.22.02.02.12.52.12.42.42.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value302286325368374333334388415413447413431
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.61.81.91.61.61.92.12.02.32.22.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.61.81.91.61.61.92.12.02.32.22.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1063231373539364034443950
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.20.10.20.20.20.20.20.20.20.20.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.20.10.20.20.20.20.20.20.20.20.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:OtherImmunology, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-01
Value32233-36617332-1422
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.0-1.80.90.00.0-0.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.0-1.80.90.00.0-0.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherImmunology jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value11699113117112114131146142138152159170
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.50.60.60.60.60.70.70.70.80.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.50.60.60.60.60.70.70.70.80.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value104220186170163164156136134120127130127
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.51.10.90.80.80.80.80.70.70.60.60.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.51.10.90.80.80.80.80.70.70.60.60.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value579544508535523495490492478470467454430
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.62.52.62.62.42.42.42.42.32.42.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.62.52.62.62.42.42.42.42.32.42.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value155183198183226221255236276232238255247
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.91.00.91.11.11.31.11.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.91.00.91.11.11.31.11.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value170160167182179178175188196197194207207
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.80.90.90.90.90.91.01.01.01.11.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.80.90.90.90.90.91.01.01.01.11.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value990103511361107110212381379132013891466164715301672
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.05.55.45.56.16.86.36.97.38.48.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.05.55.45.56.16.86.36.97.38.48.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value703817778818788831786845804856871915883
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.43.93.84.03.94.13.94.14.04.24.44.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.43.93.84.03.94.13.94.14.04.24.44.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value253309299319305317297329308319291302
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.51.41.61.51.61.51.61.51.61.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.51.41.61.51.61.51.61.51.61.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value529515586563524482536548518490476439428
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.52.82.72.62.42.62.62.62.42.42.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.52.82.72.62.42.62.62.62.42.42.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value18191700169815581405144413101341106110811124983823
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.88.28.27.67.07.16.46.45.35.45.75.24.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.88.28.27.67.07.16.46.45.35.45.75.24.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value654686677672685674654675696669662643642
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.33.33.33.43.33.23.23.53.33.43.43.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.33.33.33.43.33.23.23.53.33.43.43.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value29627029023521717517112672
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.31.41.11.10.90.80.60.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.31.41.11.10.90.80.60.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value25020821020319818117117114013012490
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.01.01.00.90.80.80.70.60.60.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.01.01.00.90.80.80.70.60.60.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:VELCADE, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value108115149224263252271280313271273290280
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.71.11.31.21.31.31.61.31.41.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.71.11.31.21.31.31.61.31.41.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:VELCADE jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Xarelto, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value527609613549542608612679578710635642513
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.93.02.72.73.03.03.32.93.53.23.42.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.93.02.72.73.03.03.32.93.53.23.42.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Xarelto jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value690677741698679786958909845755669558523
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.33.63.43.43.94.74.44.23.73.43.02.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.33.63.43.43.94.74.44.23.73.43.02.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

jnj:BabyCare, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value92859199871161208997
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.40.60.60.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.40.60.60.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:BabyCare, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value269336326344307357352367360
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.61.61.71.51.81.71.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.61.61.71.51.81.71.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value659582559663588612543637611
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.22.82.73.22.93.02.73.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.22.82.73.22.93.02.73.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value458568592539502499535472473
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.72.92.62.52.42.62.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.72.92.62.52.42.62.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value689542477484507491440454465
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.32.62.32.42.52.42.22.22.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.32.62.32.42.52.42.22.22.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value659653621580580657608612607
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.13.02.82.93.23.02.93.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.23.13.02.82.93.23.02.93.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value176159156155151165158157157
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.80.80.80.80.80.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.80.80.80.80.80.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value219233223234216234226236222
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.11.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.11.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value433333343
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value228250252250222254266276240
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.21.21.11.21.31.31.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.21.21.11.21.31.31.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1199810913210292106135103
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.50.60.50.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.50.50.60.50.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value525759615356586560
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:ADVANCED, country:US, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value381428409396404441421402393
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.82.12.01.92.02.22.11.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.82.12.01.92.02.22.11.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ADVANCED, us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value567647602633576614555603573
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.73.12.93.12.93.02.72.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.73.12.93.12.93.02.72.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, country:US, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value523784159738576866
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.20.40.10.50.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.20.40.10.50.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value118115109123116112100115107
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.60.60.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.60.60.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, country:US, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value346311339333321289319320309
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.51.61.61.61.41.61.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.51.61.61.61.41.61.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value467522555509502527516524498
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.52.72.52.52.62.52.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.52.72.52.52.62.52.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:DARZALEX, country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value463444402369352323318298264
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.11.91.81.81.61.61.41.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.11.91.81.81.61.61.41.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:DARZALEX, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value474385363405277261180213168
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.31.91.82.01.41.30.91.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.31.91.82.01.41.30.91.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value121412121216131514
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value212209206198199177189196196
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.01.01.00.90.90.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.01.01.00.90.90.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ERLEADA, country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-03-31
Value11958
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0

jnj:ERLEADA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-03-31
Value243
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0

jnj:GENERAL, country:US, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value463451443443425469423436423
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.22.12.22.12.32.12.12.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.22.12.22.12.32.12.12.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:GENERAL, us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value690720659674665712657733704
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.53.23.33.33.53.23.53.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.53.23.33.33.53.23.53.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, country:US, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value206230204216213220201211209
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.11.01.11.11.11.01.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.11.01.11.11.11.01.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value132147133147148145129149154
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.60.70.70.70.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.60.70.70.70.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value432392447367349318334250227
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.92.21.81.71.61.61.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.92.21.81.71.61.61.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value599483475463435385371370360
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.32.32.32.21.91.81.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.32.32.32.21.91.81.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, country:US, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value544564554506483485468438400
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.72.72.52.42.42.32.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.72.72.52.42.42.32.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value339308297312307278281282296
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.51.41.51.51.41.41.41.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.51.41.51.51.41.41.41.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value117125125132154188150169204
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.60.60.80.90.70.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.60.60.80.90.70.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value585255434940404644
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.20.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.20.20.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, country:US, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value214239209218223239215229228
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.21.01.11.11.21.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.21.01.11.11.21.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value130156136153146153126153159
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.80.70.70.70.80.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.80.70.70.70.80.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value229185206203172189182180149
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.10.91.01.00.90.90.90.90.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.10.91.01.00.90.90.90.90.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value160143140146133134128131122
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.70.70.70.70.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.70.70.70.70.70.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTHERNEUROSCIENCE, country:US, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value757068626660505376
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.30.30.30.20.30.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.30.30.30.20.30.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTHERNEUROSCIENCE, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value360314316340379349359384418
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.51.51.71.91.71.81.82.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.51.51.71.91.71.81.82.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8578911071041028697132
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.50.50.40.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.50.50.40.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value441617202122202320
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value217209234260271231248291283
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.31.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.31.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value621615161517161714
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherImmunology, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value322333232
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherImmunology us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value293233313034353646
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.20.20.20.10.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.20.20.20.10.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8767808682809611096
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.40.40.40.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.40.40.40.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value2212291787671715135
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.60.40.40.40.30.30.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.60.40.40.40.30.30.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value829795928793858599
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.40.40.50.40.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.40.40.50.40.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value396390373344315322297277273
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.91.81.71.61.61.51.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.91.81.71.61.61.51.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value184155135191208173193215205
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.70.70.91.00.80.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.70.70.91.00.80.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value76118126113148151178156189
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.50.70.70.90.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.50.70.70.90.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value796572707870778087
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.30.40.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.30.40.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, country:US, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value767779817777768082
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value94828910110210199108114
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.40.50.50.50.50.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.40.50.50.50.50.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, country:US, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value625755749801774843987918916
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.63.63.93.94.14.94.44.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.63.63.93.94.14.94.44.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, jnj:UNITEDSTATESExports, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1106888627690100104142
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.30.40.30.40.40.50.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.30.40.30.40.40.50.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade jnj:UNITEDSTATESExports jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value256212299244252305292298331
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.41.21.31.51.41.41.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.41.21.31.51.41.41.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, country:US, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value423488472490465496473498463
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.42.32.42.32.42.32.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.42.32.42.32.42.32.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value280329306328323335313347341
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.61.51.61.61.61.51.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.61.51.61.61.61.51.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, country:US, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value93117120128125137133139131
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.60.60.70.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.60.60.60.60.70.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value160191180191180180164190177
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.90.90.90.90.90.80.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.90.90.90.90.90.80.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, country:US, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value272302313281263272281274224
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.51.51.41.31.31.41.31.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.51.51.41.31.31.41.31.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value258213273282261210255274294
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.31.41.31.01.31.31.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.01.31.41.31.01.31.31.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, country:US, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value12171194121210588821009889919652
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.95.85.85.14.44.94.44.43.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.95.85.85.14.44.94.44.43.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value603506487499523435421422409
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.42.32.42.62.12.12.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.42.32.42.62.12.12.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, country:US, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value407413415407417403395394407
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.02.02.02.12.01.91.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.02.02.02.12.01.91.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value247273262265268271259281289
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.31.31.31.31.31.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.31.31.31.31.31.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, country:US, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value18719922117616814214310266
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.91.01.10.90.80.70.70.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.91.01.10.90.80.70.70.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value109716959493328246
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.30.30.30.20.20.10.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.30.30.30.20.20.10.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value212178185175176165154155124
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.90.90.90.90.80.80.70.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.90.90.90.90.80.80.70.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value383025282216171616
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:VELCADE, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value108115149224263252271280313
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.71.11.31.21.31.31.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.71.11.31.21.31.31.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:VELCADE us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Xarelto, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value527609613549542608612679578
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.93.02.72.73.03.03.32.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.93.02.72.73.03.03.32.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Xarelto country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value139194233198185351527486407
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.91.11.00.91.72.62.32.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.91.11.00.91.72.62.32.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value552483508500494435431423438
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.72.32.52.42.52.12.12.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.72.32.52.42.52.12.12.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementBusinessSegments

jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value362535673469354433183536341535043398354033563478322834323261341931953320331434833390360635893744355737533611365836753652358136193595366837403793368236103567364737664249398938543711
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.517.216.717.216.617.316.816.817.017.517.118.518.219.018.318.518.318.619.419.619.519.819.419.219.620.420.520.521.020.821.022.022.322.623.422.922.823.123.823.824.125.726.525.324.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.517.216.717.216.617.316.816.817.017.517.118.518.219.018.318.518.318.619.419.619.519.819.419.219.620.420.520.521.020.821.022.022.322.623.422.922.823.123.823.824.125.726.525.324.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-30
Value5932663263836489645966686587697267676974659967266293615964096109609463586258657172427060
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.732.030.831.632.332.732.433.533.834.533.635.735.434.634.734.935.635.736.035.637.139.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.732.030.831.632.332.732.433.533.834.533.635.735.434.634.734.935.635.736.035.637.139.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value11134105481087710529102441019010346103549844968196958635824582328400865481788064769479467726799983078509749872967036702567686525640262916133609459826233605957105495555356385993524954985780
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax53.850.852.551.251.250.050.849.749.247.949.345.846.445.547.146.846.845.345.044.744.543.845.043.641.439.740.039.338.737.237.538.238.037.537.437.637.536.536.736.236.136.234.836.138.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax53.850.852.551.251.250.050.849.749.247.949.345.846.445.547.146.846.845.345.044.744.543.845.043.641.439.740.039.338.737.237.538.238.037.537.437.637.536.536.736.236.136.234.836.138.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:MedicalDevices, jnj:InterventionalSolutions



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value727774741750732686653667640621553573549
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.53.73.63.63.73.43.23.23.23.12.83.03.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.53.73.63.63.73.43.23.23.23.12.83.03.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value2038227321382224220422622111226222502286220422932275
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.811.010.310.811.011.110.410.911.211.311.212.212.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.811.010.310.811.011.110.410.911.211.311.212.212.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value2100244223112353239525872376251524232558234623842271
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.111.811.111.412.012.711.712.112.112.711.912.712.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.111.811.111.412.012.711.712.112.112.711.912.712.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value106711411193116111291133113211731115111910911055
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.25.55.85.65.65.65.65.65.65.55.65.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.25.55.85.65.65.65.65.65.65.55.65.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1160125613161275134513901391151815171622158516051475
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.66.16.36.26.76.86.87.37.68.08.18.58.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.66.16.36.26.76.86.87.37.68.08.18.58.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value3638352237113466325133423398333830423086326929592930
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.617.017.916.916.216.416.716.015.215.316.615.716.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.617.017.916.916.216.416.716.015.215.316.615.716.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value920866839862846802823849830800813792749
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.24.04.24.23.94.04.14.14.04.14.24.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.24.04.24.23.94.04.14.14.04.14.24.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1658156615951538162915001490152815591524149814671497
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.07.57.77.58.17.47.37.37.87.57.67.88.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.07.57.77.58.17.47.37.37.87.57.67.88.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value3013271627612697251824892588245623112039189817271594
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.613.113.313.112.612.212.711.811.510.19.79.29.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.613.113.313.112.612.212.711.811.510.19.79.29.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value745623654690656667656665585610632850
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.03.23.43.33.33.23.22.93.03.20.50.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.03.23.43.33.33.23.22.93.03.20.50.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:StatementGeographical

country:US



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-03
Value1069910774107911040310129106291066410640995110469102909726937893819572932187918911869286048842913282047925794680257791736072196868744776087131
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax51.751.952.150.650.652.152.451.149.751.852.451.652.852.651.853.351.450.150.047.147.946.845.345.144.445.845.744.744.742.944.947.047.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax51.751.952.150.650.652.152.451.149.751.852.451.652.852.651.853.351.450.150.047.147.946.845.345.144.445.845.744.744.742.944.947.047.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:AsiaPacificAfrica



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-01
Value3663398939713780371838403694348333823076321132782983304632243003330833593444333133303354321634543222
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.719.219.318.918.318.418.517.718.017.318.017.717.117.818.117.318.118.217.718.418.918.818.420.319.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax17.719.219.318.918.318.418.517.718.017.318.017.717.117.818.117.318.118.217.718.418.918.818.420.319.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:AsiaPacificAfrica100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WesternHemisphereExcludingUS



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-01
Value1502148814551503155015401567156914991454139615421331146315011639178218201863169518421905178318241728
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.37.27.17.57.67.47.88.08.08.27.88.37.68.68.49.49.89.99.69.410.510.710.210.710.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.37.27.17.57.67.47.88.08.08.27.88.37.68.68.49.49.89.99.69.410.510.710.210.710.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WesternHemisphereExcludingUS100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

srt:Europe



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value4827446147334609441648104797
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.321.523.023.021.723.124.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.321.523.023.021.723.124.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax srt:Europe100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-02
Value99929973993810159989297659684101901005897269360911383888439
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.348.147.949.449.447.947.648.950.348.247.648.447.247.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.348.147.949.449.447.947.648.950.348.247.648.447.247.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

country:US, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value174014701394153714381479137014761436
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.47.16.77.57.27.36.77.17.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.47.16.77.57.27.36.77.17.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value289831353057308331093214319732653161
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.015.114.715.015.515.815.715.715.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.015.114.715.015.515.815.715.715.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value606161696340578355825936609758995354
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.329.730.628.127.929.130.028.326.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.329.730.628.127.929.130.028.326.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value188520972075200718802057204520281962
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.110.110.09.89.410.110.19.79.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.110.110.09.89.410.110.19.79.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value303434973326340633503454339037073606
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.716.916.016.616.716.916.717.818.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.716.916.016.616.716.916.717.818.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value507343794537474646624254424944554490
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.521.121.923.123.320.920.921.422.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.521.121.923.123.320.920.921.422.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

country:US, jnj:MedicalDevices, jnj:InterventionalSolutions



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value365377357366343336320323304
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.81.71.81.71.61.61.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.81.71.81.71.61.61.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value125013691301133113181358128413321307
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.06.66.36.56.66.76.36.46.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.06.66.36.56.66.76.36.46.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8449619409261001109410161022993
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.14.64.54.55.05.45.04.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.14.64.54.55.05.45.04.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value439428459461446426452459440
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.12.12.22.22.22.12.22.22.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.12.12.22.22.22.12.22.22.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8069309559029471049102611011103
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.94.54.64.44.75.15.05.35.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.94.54.64.44.75.15.05.35.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value241025172582237921632356240023172000
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.612.112.511.610.811.611.811.110.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.612.112.511.610.811.611.811.110.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value436435418387357372345328333
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.12.12.01.91.81.81.71.61.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.12.12.01.91.81.81.71.61.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value748747785664723660651639624
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.63.83.23.63.23.23.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.63.83.23.63.23.23.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1175115311711013962106312501085933
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.75.65.64.94.85.26.15.24.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.75.65.64.94.85.26.15.24.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value486388427439430436425429361
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.31.92.12.12.12.12.12.11.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.31.92.12.12.12.12.12.11.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:InterventionalSolutions



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value362398382385389350333344336
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.91.81.91.91.71.61.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.91.81.91.91.71.61.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value788904837894885904827930943
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.84.44.04.34.44.44.14.54.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.84.44.04.34.44.44.14.54.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value125714811371142713941493136014931430
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.17.16.66.97.07.36.77.27.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.17.16.66.97.07.36.77.27.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value628713734701682707680714675
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.43.53.43.43.53.33.43.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.43.53.43.43.53.33.43.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value354327360373398341365417414
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.61.71.82.01.71.82.02.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.61.71.82.01.71.82.02.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1228100511291087108898699810211042
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.94.85.45.35.44.84.94.95.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.94.85.45.35.44.84.94.95.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value483430421475489430478521497
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.12.02.32.42.12.32.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.12.02.32.42.12.32.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value910819810875905840839889935
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.43.93.94.34.54.14.14.34.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.43.93.94.34.54.14.14.34.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value183915631590168415561426133813711378
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.97.57.78.27.87.06.66.66.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.97.57.78.27.87.06.66.66.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value260235227251226231231236224
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.11.11.21.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.11.11.21.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0

Revenues

us-gaap:Revenues



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
Percentage of Revenues100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Sales Revenue Goods Net

Cost Of Goods And Services Sold

us-gaap:CostOfGoodsAndServicesSold



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-01
Value70627134686769406615696165896927661472596925
Percentage of CostOfGoodsAndServicesSold100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax34.134.433.133.833.034.132.433.333.135.935.2

Cost Of Goods Sold

Gross Profit

us-gaap:GrossProfit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value136291361313862136221340613433137591390313395129521274813016123801257212334131461215312138118781243012092124011306813456126601240012231123881195111555114551133211224109171093311425113951060410388107001110311239106471078910775
Percentage of GrossProfit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax65.965.666.966.267.065.967.666.766.964.164.969.169.769.469.271.169.568.169.569.969.667.970.869.069.967.669.669.368.365.867.268.869.567.268.368.870.567.869.369.871.067.970.670.871.7

Selling General And Administrative Expense

us-gaap:SellingGeneralAndAdministrativeExpense



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value52036039537455465219599155435743526360255396526247374772517646885081538448475822546854815183531453765223522849655015524052155056470947564779
Percentage of SellingGeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax25.129.125.927.026.129.427.227.626.329.827.527.926.726.828.026.829.730.327.931.929.628.128.630.230.129.830.730.131.132.731.431.331.431.030.6

Operating Income Loss

us-gaap:ConsolidationItems

us-gaap:OperatingIncomeLoss

us-gaap:CorporateNonSegment



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value120176231147230303312328316247233293192256282252243249
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.81.10.71.11.51.61.71.71.41.31.61.11.51.61.51.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CorporateNonSegment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value662918237272456946535276579351185064582255145197548643786023582770535875
Percentage of OperatingIncomeLoss5524.21035.83148.13108.22023.01741.31856.71560.41602.52357.12366.51773.72857.31710.22135.82312.32902.52359.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax32.08.835.422.822.925.329.026.026.932.830.928.131.425.633.933.538.230.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, jnj:Consumer



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value770653406741510829548878658596679571566811317644407703
Percentage of OperatingIncomeLoss641.7371.0175.8504.1221.7273.6175.6267.7208.2241.3291.4194.9294.8316.8112.4255.6167.5282.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.73.22.03.72.54.02.74.53.53.43.83.13.24.71.83.72.23.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:Consumer0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value20251392318914971267796157913839921563152693915768351584222133991703
Percentage of OperatingIncomeLoss1687.5790.91380.51018.4550.9262.7506.1421.6313.9632.8654.9320.5820.8326.2561.7881.31398.8683.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.86.715.57.56.23.87.97.05.38.88.65.19.04.98.912.818.48.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:MedicalDevices0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:Pharmaceutical



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value3834-2223677233128763651366628573414366333093687334427324122296232473469
Percentage of OperatingIncomeLoss3195.0-126.11591.81585.71250.41205.01175.0871.01080.41483.01420.21258.41741.71067.21461.71175.41336.21393.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.5-1.117.911.614.117.518.314.518.120.618.619.919.116.023.217.017.617.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:Pharmaceutical0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Interest Expense

us-gaap:InterestExpense



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value25854883102250243253259274229227204192190160123131138139130128136105118125135143147134129125108101108
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.40.20.40.51.21.21.21.31.41.21.21.11.11.00.90.70.70.80.80.70.70.80.60.70.70.80.90.90.80.80.80.70.70.7

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value679-16-4214168322-978-3-364-609236-58816054-55739-420931348-9631345-226-86-943-172-51590-2008611308-20613292-181594
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.3-0.1-20.38.20.1-4.8-0.0-1.7-0.30.01.2-3.10.90.3-3.00.2-2.55.22.0-5.37.3-1.2-0.5-5.4-1.0-2.90.5-12.23.81.9-1.20.11.9-0.110.2

Income Loss From Continuing Operations Before Income Taxes Domestic

Income Loss From Continuing Operations Before Income Taxes Foreign

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value713208-106143467380489101911141327310269211153100990710027641225125518220611300697685960764966627113590964610348027711754
Percentage of IncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.41.0-0.57.03.40.42.44.95.665.75.24.96.55.74.95.74.56.97.21.011.26.73.83.95.44.45.73.87.05.73.96.45.45.011.2

Profit Loss

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-02
Value5444118961553454406417855190425151154801426436815066255157621742-28192374396449424446371226184247-25650021324
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.35.729.917.320.08.625.921.627.227.023.919.929.014.932.410.0-15.412.920.327.325.320.815.024.9-1.631.08.3

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

Net Income Loss

us-gaap:NetIncomeLoss



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value579640101753560737493042393439544367-107133764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.019.38.527.318.714.919.319.021.8-53.019.220.324.921.124.021.624.618.119.625.424.913.825.722.226.119.217.021.420.014.617.48.524.21.320.016.721.512.422.822.529.013.322.221.123.3

us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value579640101753560737493042393439544367
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.019.38.527.318.714.919.319.021.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.0

Net Income Loss Attributable To Noncontrolling Interest

Assets

us-gaap:Assets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value1550171577281555211551171500271529541557031553651566251573031556581528071449181412081403691398141362311334111332661320361285901311191320971352001333301326831269331243251215361213471189511157501161941136441118211121141081501029089468284912
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Liabilities

us-gaap:Liabilities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value937239825797311943329107293202910779247693370971438167980885745777079067600673416358462261617126090560712613675550657152567485863057129546605468156521551905531654828565645029449982482874632944094
Percentage of Liabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets60.562.362.660.860.760.958.559.559.661.852.552.951.550.148.248.246.746.746.346.147.246.842.042.342.644.245.044.045.046.646.447.847.249.845.044.644.645.046.6

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value15501715772815552115511715002715295415570315536515662515730315565815280714491814120814036913981413623113341113326613203612859013111913209713520013333013268312693312432512153612134711895111575011619411364411182111211410815010290894682
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Assets Current

us-gaap:AssetsCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value442264527444333417994198746033471944543842768430884182938789633476503263319662916273860210634946100158192593115997360119573695640752176512734722846116447914161557007543165344352673492214730739541
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets28.528.728.526.928.030.130.329.227.327.426.925.443.746.145.147.446.145.147.646.245.345.245.444.543.042.541.141.238.938.037.736.049.147.847.847.045.546.041.8

Cash

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032008-12-282007-12-30
Value155301730516249143761473418107160561756914639178241572112598209091897218205186401386113732136391063911988145231381814236197222092717204173071485514911154861404230267245421561714974223561935514338127131374315810107687770
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.011.010.49.39.811.810.311.39.311.310.18.214.413.413.013.310.210.310.28.19.311.110.510.514.815.813.613.912.212.313.012.126.021.614.013.420.718.80.00.00.016.712.70.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableforsaleSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value4275311032091865417181547847
Percentage of CashAndCashEquivalentsAtCarryingValue27.518.019.713.028.345.048.9
Percentage of Assets2.82.02.11.22.85.35.0
Percentage of Assets us-gaap:AvailableforsaleSecurities0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value112551419513040125111056399538209
Percentage of CashAndCashEquivalentsAtCarryingValue72.582.080.387.071.755.051.1
Percentage of Assets7.39.08.48.17.06.55.3
Percentage of Assets us-gaap:HeldtomaturitySecurities0.00.00.00.00.00.00.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value15151420281012
Percentage of CashAndCashEquivalentsAtCarryingValue0.10.10.10.10.20.10.1
Percentage of Assets0.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.0

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value4260309531951845414381447835
Percentage of CashAndCashEquivalentsAtCarryingValue27.417.919.712.828.145.048.8
Percentage of Assets2.72.02.11.22.85.35.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:USTreasuryAndGovernment0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, jnj:OtherReverseRepurchaseAgreements



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value473375241219350443479
Percentage of CashAndCashEquivalentsAtCarryingValue3.02.21.51.52.42.43.0
Percentage of Assets0.30.20.20.10.20.30.3
Percentage of Assets us-gaap:HeldtomaturitySecurities jnj:OtherReverseRepurchaseAgreements0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:BankTimeDeposits



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value765906691651533485932
Percentage of CashAndCashEquivalentsAtCarryingValue4.95.24.34.53.62.75.8
Percentage of Assets0.50.60.40.40.40.30.6
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:BankTimeDeposits0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:Cash



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value2499263726672615277826192575
Percentage of CashAndCashEquivalentsAtCarryingValue16.115.216.418.218.914.516.0
Percentage of Assets1.61.71.71.71.91.71.7
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:Cash0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value10398891159264449200
Percentage of CashAndCashEquivalentsAtCarryingValue6.75.17.11.83.01.2
Percentage of Assets0.70.60.70.20.30.1
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:MoneyMarketFunds



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value2424286414811368419533971763
Percentage of CashAndCashEquivalentsAtCarryingValue15.616.69.19.528.518.811.0
Percentage of Assets1.61.81.00.92.82.21.1
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:MoneyMarketFunds0.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value39656182701420682260
Percentage of CashAndCashEquivalentsAtCarryingValue25.538.048.814.014.1
Percentage of Assets2.64.04.51.41.5
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase0.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value901496193801900
Percentage of CashAndCashEquivalentsAtCarryingValue0.60.93.82.61.30.0
Percentage of Assets0.10.10.40.20.10.0
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:SovereignDebtSecurities0.00.00.00.00.00.0

Accounts Receivable Net Current

us-gaap:AccountsReceivableNetCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1487414481148011465314115140981404814111141661349013155132831230011699117981206211406107341136611968115331098511615122571211611713120271161411515113091117510992109821058110552109821086197749646
Percentage of AccountsReceivableNetCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets9.69.29.59.49.49.29.09.19.08.68.58.78.58.38.48.68.48.08.59.19.08.48.89.19.18.89.59.39.59.39.49.59.59.39.49.810.09.510.2

Inventory Net

us-gaap:InventoryNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value886890209173926390868599867888109014876595219699887881448488852381708053820682988085818484198155800978788124782276917495780976976800628564286413620053785180
Percentage of InventoryNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.75.75.96.06.15.65.65.75.85.66.16.36.15.86.06.16.06.06.26.36.36.26.46.06.05.96.46.36.36.26.66.65.95.55.75.75.75.25.5

Inventory Finished Goods

Inventory Raw Materials And Supplies

Prepaid Expense And Other Assets Current

us-gaap:PrepaidExpenseAndOtherAssetsCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value2358239222202411259926992896256926412537292229542826328226003122330730473010305837313486310739823932400333123425326030842789289426832633305632902273
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.51.51.41.61.71.81.91.71.71.61.91.92.02.31.92.22.42.32.32.32.92.72.42.92.93.02.62.82.72.52.32.52.32.32.72.92.2

Land

Machinery And Equipment Gross

Noncurrent Assets

Property Plant And Equipment Gross

us-gaap:PropertyPlantAndEquipmentGross



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value432474333242625429054226241851415204129341996414664092840075386963777338373377793743036648363973611235403366853644836947362483713336432354013469534654340823329732550318293173632435318053042629251
Percentage of PropertyPlantAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets27.927.527.427.728.227.426.726.626.826.426.326.226.726.727.327.027.527.527.327.427.528.027.627.327.228.028.728.528.528.628.728.828.028.028.428.929.429.630.9

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value258462567425577256572526224816248912466124956244612430023617225052186122278218072146620743208462052920039205592064420792202522042320305196071897418557182371767517726170901710117461167211587314492
Percentage of AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets16.716.316.416.516.816.216.015.915.915.615.615.515.515.515.915.615.815.515.615.515.615.715.615.415.215.416.015.815.615.315.315.315.315.015.315.615.515.415.3

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value17401176581704817248170001703516629166321704017005166281645816191159121609515972159641590515551155831536416126158041615515996167101612715794157211609715845156221482414739146351497415084145531475914365
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets11.211.211.011.111.311.110.710.710.910.810.710.811.211.311.511.411.711.911.711.811.912.312.011.912.012.612.712.712.913.313.313.512.813.013.113.413.914.115.616.9

Goodwill

us-gaap:Goodwill



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value33471336393329133661314503045330702303463114931906313083123424844228052317122104218482162921279214932134521832216362198922178227982285222337223492242421777214121633916138160491624316126152941486213719
Percentage of Goodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets21.621.321.421.721.019.919.719.519.920.320.120.417.116.116.515.816.016.216.016.316.616.716.416.316.617.218.018.018.418.518.318.514.114.214.414.514.914.915.716.2

us-gaap:BusinessAcquisition

jnj:VerbSurgicalInc.



Period End2020-03-29
Value200
Percentage of Goodwill0.6
Percentage of Assets0.1
Percentage of Assets jnj:VerbSurgicalInc.0.0

us-gaap:StatementBusinessSegments

jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-022010-01-03
Value95139736959598179730867087408578889988758848863083448263857575157412724072087406727476757984832485128531861784118477851984598179847082988335846481448074
Percentage of Goodwill28.428.928.829.230.928.528.528.328.627.828.327.633.636.237.034.033.933.533.934.534.135.236.937.938.437.437.737.737.938.038.838.251.851.451.952.153.254.3
Percentage of Assets6.16.26.26.36.55.75.65.55.75.65.75.65.85.96.15.45.45.45.45.65.75.96.06.26.46.46.86.87.07.07.17.17.37.37.57.57.98.5
Percentage of Assets jnj:Consumer0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.035.20.00.00.036.00.00.00.035.30.00.00.034.30.00.034.332.7

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-28
Value14884147341471914740127321272012850127261299413922137741371413646117021170211699115241150011454114681145911531
Percentage of Goodwill44.543.844.243.840.541.841.941.941.743.644.043.954.951.350.552.952.753.253.853.453.752.8
Percentage of Assets9.69.39.59.58.58.38.38.28.38.98.89.09.48.38.38.48.58.68.68.78.98.8
Percentage of Assets jnj:MedicalDevices0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-022010-01-03
Value90749169897791048988906391129042925691098686889028542840289428902912288926172619261226262092205920652068205417781762179217681742174217211768181512251244
Percentage of Goodwill27.127.327.027.028.629.829.729.829.728.527.728.511.512.512.513.113.313.412.312.212.212.09.79.49.39.19.08.07.98.08.18.110.710.711.011.28.08.4
Percentage of Assets5.95.85.85.96.05.95.95.85.95.85.65.82.02.02.12.12.12.22.02.02.02.01.61.51.51.61.61.41.41.51.51.51.51.51.61.61.21.3
Percentage of Assets jnj:Pharmaceutical0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.010.20.00.00.08.70.00.00.07.70.00.00.07.20.00.06.15.8

Intangible Assets Net Excluding Goodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value473384764347846493324689847611486375005652365532285456954942294662687627642256942584025764259882701727025272222630427122276432794728467277042800928752287902919918157181381822518378186871671616323
Percentage of IntangibleAssetsNetExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets30.530.230.831.831.331.131.232.233.433.835.136.020.319.019.718.419.019.319.520.521.020.819.920.120.721.122.422.323.023.724.225.215.616.016.316.417.316.217.2

Finite Lived Intangible Assets Net

us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsNet

jnj:PatentsAndTrademarks



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value2235723480239562508225415254102640126556283862920429947302586085544557983659347235543611411141994374437746174899501851645231532654745557558250084971
Percentage of FiniteLivedIntangibleAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets14.414.915.416.216.916.617.017.118.118.619.219.84.23.94.12.62.52.72.73.13.33.33.33.43.73.84.14.24.44.54.74.84.34.4
Percentage of Assets jnj:PatentsAndTrademarks0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OtherIntangibleAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value123561259412725129881318013011130081314413393127411294412995129121110011419115571178611767121021250712516127431318113781139761415514165141291429814725147551466751515284
Percentage of FiniteLivedIntangibleAssetsNet55.353.653.151.851.951.249.349.547.243.643.242.9212.2203.9196.9315.9339.5331.1335.1304.2298.1291.3301.1298.5285.3282.1274.3270.1268.5269.0265.5262.8102.9106.3
Percentage of Assets8.08.08.28.48.88.58.48.58.68.18.38.58.97.98.18.38.78.89.19.59.79.710.010.210.510.711.211.411.812.112.412.74.44.6
Percentage of Assets us-gaap:OtherIntangibleAssets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Intangible Assets Net Including Goodwill

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value504256955307543051594182446544214518497150215273469044354245397741634413380438553605323250336435645949492715247737233417352138913956377339054193370539423690
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets3.33.63.43.53.42.72.92.82.93.23.23.53.23.13.02.83.13.32.92.92.82.53.84.84.83.72.12.03.12.83.03.43.43.33.53.73.43.83.9

us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8261148863963830511697697731
Percentage of OtherAssetsNoncurrent16.420.216.317.716.112.215.615.816.2
Percentage of Assets0.50.70.60.60.60.30.40.40.5
Percentage of Assets us-gaap:EquitySecurities jnj:EquityInvestmentswithReadilyDeterminableValue0.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value694712699677698681639624573
Percentage of OtherAssetsNoncurrent13.812.513.212.513.516.314.314.112.7
Percentage of Assets0.40.50.40.40.50.40.40.40.4
Percentage of Assets us-gaap:EquitySecurities jnj:EquityInvestmentswithoutReadilyDeterminableValue0.00.00.00.00.00.00.00.00.0

Liabilities Current

us-gaap:LiabilitiesCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value336893596435162313532911131230274372748827081305373180628872251192628723230215362213427747252602451223836250852298224359238402567525835237672252424262239352384821198228112168620985240112307221731
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets21.722.822.620.219.420.417.617.717.319.420.418.917.318.616.515.416.220.819.018.618.519.117.418.017.919.420.419.118.520.020.120.618.220.119.418.722.222.423.0

Debt Current

Long Term Debt Current

Accounts Payable Current

us-gaap:AccountsPayableCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value741185447491691269237537700065166443731063906135608269185971606159656668592861406719763366036193611362666055568753725831534451455085572557305689570156235541
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.85.44.84.54.64.94.54.24.14.64.14.04.24.94.34.34.45.04.44.75.25.85.04.64.64.74.84.64.44.84.54.44.45.05.15.15.35.55.9

Accrued Income Taxes Current

us-gaap:AccruedIncomeTaxesCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value19302266250517011025818109692815591854118375911339717986909687509319161243500153510558627701711956117810641502125991485413368081007578442
Percentage of AccruedIncomeTaxesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.21.41.61.10.70.50.70.61.01.20.80.50.80.70.60.50.70.60.70.71.00.41.20.80.60.61.30.81.00.91.31.10.80.81.20.70.90.60.5

Long Term Debt

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value2539326494269192769927660276842948029405298373067526675273632701522442235462453520233128571407314085149381512213152133031334313328974896431136311489114281152513010129691303113680925591568223
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets16.416.817.317.918.418.118.918.919.019.517.117.918.615.916.817.514.99.610.610.711.611.510.09.810.010.07.77.89.39.59.610.011.211.411.712.28.68.98.7

Deferred Tax Liabilities Noncurrent

Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value109441173411381101028928858985389281887690179102101179526953694141006297491024193038973860480347758737372717854889585698197855292079487105381063174737227700165675947
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets7.17.47.36.56.05.65.56.05.75.75.86.66.66.86.77.27.27.77.06.86.76.15.95.55.55.97.06.96.77.07.78.29.19.46.76.46.56.46.3

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-282007-12-30
Value6129459471582106078558955597526462662889632556016073979719227034170418727697247372647711507155471131678786975276591780487658274053698046966566855648266376160434613665708061527621325986356579505884251143319
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets39.537.737.439.239.339.141.540.540.438.247.547.148.549.951.851.853.353.353.753.952.853.258.057.757.455.855.056.055.053.453.652.252.850.255.055.455.455.053.450.10.0

us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value-6696-6891-5716-5852-5989-6158-5593-5779-5964-6150-5623-5743-5861-5980-5298-6317-3009
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-10.9-11.6-9.8-9.6-10.2-10.3-8.7-9.2-9.4-10.2-7.6-8.0-8.3-8.5-7.4-9.1-4.1
Percentage of Assets-4.3-4.4-3.7-3.8-4.0-4.0-3.6-3.7-3.8-3.9-3.6-3.8-4.0-4.2-4.0-4.8-2.3
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302017-12-312017-01-01
Value675-295-374-341-401-19570-285
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1.1-0.5-0.6-0.6-0.7-0.30.1-0.4
Percentage of Assets0.4-0.2-0.2-0.2-0.3-0.10.0-0.2
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value201100-100232269354321411604257106
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.00.00.00.00.00.0-0.00.00.00.40.40.50.50.60.80.40.1
Percentage of Assets0.00.00.00.00.00.0-0.00.00.00.10.20.20.20.30.50.20.1
Percentage of Assets us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-28
Value-16243-15891-15533-14969-15517-15222-14647-14777-12608-13199-12747-13234-14522-14901-13165-10722-2860-5810-5632-3531-3058-4955
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-26.5-26.7-26.7-24.6-26.3-25.5-22.7-23.5-19.9-21.9-17.2-18.4-20.6-21.2-18.5-15.4-3.9-9.0-9.9-6.2-6.0-11.7
Percentage of Assets-10.5-10.1-10.0-9.7-10.3-10.0-9.4-9.5-8.0-8.4-8.2-8.7-10.0-10.6-9.9-8.2-2.2-4.8-5.0-3.4-3.2-5.8
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value-10224-8705-9444-8777-9127-8869-9069-8918-6728-7351-7450-7809-8652-9047-8435-4803-202
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-16.7-14.6-16.2-14.4-15.5-14.8-14.0-14.2-10.6-12.2-10.1-10.9-12.3-12.8-11.9-6.9-0.3
Percentage of Assets-6.6-5.5-6.1-5.7-6.1-5.8-5.8-5.7-4.3-4.7-4.8-5.1-6.0-6.4-6.3-3.7-0.2
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value1129011106591092421098091066501062161076171061231043391017931105511038799724589493859928125177773703066337955280
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest184.2186.1187.7180.7180.9177.8166.5168.7164.9169.2157.0146.0139.4120.8132.7142.3137.5139.0149.1127.6
Percentage of Assets72.870.270.270.871.169.469.168.366.664.778.377.974.267.470.971.575.674.374.60.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TreasuryStock



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value-38484-38417-38619-37175-35298-34362-31464-31577-31596-31554-28352-22684-19891-15700-18476-21659-20783-19780-19033-14388
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-62.8-64.6-66.3-61.2-59.9-57.5-48.7-50.2-50.0-52.5-40.3-31.9-28.5-21.2-28.5-37.9-36.7-39.1-44.8-33.2
Percentage of Assets-24.8-24.4-24.8-24.0-23.5-22.5-20.2-20.3-20.2-20.1-20.1-17.0-15.2-11.8-15.2-19.1-20.2-20.9-22.40.0
Percentage of Assets us-gaap:TreasuryStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Common Stock Value

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value11290111065910924210980910665010621610761710612310433910179311480511320811164311055110886010673810499010387910274810135298656972459656093745913878949387703894498724285992848808353083103812518263480836795157777370306
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets72.870.270.270.871.169.469.168.366.664.773.874.177.078.377.676.377.177.977.176.876.774.273.169.368.567.469.171.971.870.971.472.271.571.573.972.173.575.674.3

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value-16243-15891-15533-14969-15517-15222-14647-14777-12608-13199-12747-13234-14522-14901-12715-12707-12391-13165-12861-12054-13300-10722-5382-3007-2645-2860-5346-6810-6689-5810-4925-6204-4540-5632-3068-1192-2020-3531-3058-4955
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-10.5-10.1-10.0-9.7-10.3-10.0-9.4-9.5-8.0-8.4-8.2-8.7-10.0-10.6-9.1-9.1-9.1-9.9-9.7-9.1-10.3-8.2-4.1-2.2-2.0-2.2-4.2-5.5-5.5-4.8-4.1-5.4-3.9-5.0-2.7-1.1-1.9-3.4-3.2-5.8

Treasury Stock Value

us-gaap:TreasuryStockValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-282007-12-30
Value3848438417386193717535298343623146431577315963155431199311722990028352264962467823072226842145321287205981989117707158101528015700156731609416818184761931420012203172165921159206322075220783197801903314388
Percentage of TreasuryStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets24.824.424.824.023.522.520.220.320.220.120.020.420.620.118.917.716.917.016.116.116.015.213.411.711.511.812.312.913.815.216.217.317.519.118.918.419.220.220.922.40.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value3358639875275948354362446272360661052913176361255200287243654654552939232277279523163690
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.230.836.328.917.730.630.818.030.216.410.135.829.216.523.925.228.421.713.017.314.323.6

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-581-1344-1645-1788-14172228-4269-925-505-936-1537-1001-3554-1789-2922735-8092-2026-140340561440-1882
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-2.8-6.5-7.9-8.7-7.110.9-21.0-4.6-2.5-5.3-8.8-5.9-20.0-10.3-16.04.0-41.5-11.2-8.025.18.9-12.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-4315-4072-3893-4534-5516-6389-3477-5970-3537-150-178-1825-2503-3227-619-5716-2868-3057-777-1183-825-3822
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-20.9-19.6-18.8-22.1-27.6-31.3-17.1-29.8-17.5-0.8-1.0-10.7-14.1-18.6-3.4-31.0-14.7-16.9-4.4-7.3-5.1-24.5

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value3358639875275948354362446272360661052913176361255200287243654654552939232277279523163690
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.230.836.328.917.730.630.818.030.216.410.135.829.216.523.925.228.421.713.017.314.323.6

Net Income Loss

us-gaap:NetIncomeLoss



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value579640101753560737493042393439544367-107133764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.019.38.527.318.714.919.319.021.8-53.019.220.324.921.124.021.624.618.119.625.424.913.825.722.226.119.217.021.420.014.617.48.524.21.320.016.721.512.422.822.529.013.322.221.123.3

us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value579640101753560737493042393439544367
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.019.38.527.318.714.919.319.021.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.0

Profit Loss

Depreciation Depletion And Amortization

us-gaap:DepreciationDepletionAndAmortization



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value17471816172717051761173517311746186991289192988989599193995210131036773755734
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Increase Decrease In Inventories

us-gaap:IncreaseDecreaseInInventories



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value159-147154369-133286322-7743681901822612762249393512288449452193
Percentage of IncreaseDecreaseInInventories100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-581-1344-1645-1788-14172228-4269-925-505-936-1537-1001-3554-1789-2922735-8092-2026-140340561440-1882
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-2.8-6.5-7.9-8.7-7.110.9-21.0-4.6-2.5-5.3-8.8-5.9-20.0-10.3-16.04.0-41.5-11.2-8.025.18.9-12.0

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value6251260745837656131881965812405606397897655431496751837630586502436397
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Payments To Acquire Investments

us-gaap:PaymentsToAcquireInvestments



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value206412361167787730147132045483554550100627953136517162912984321192554273551239810363246
Percentage of PaymentsToAcquireInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-4315-4072-3893-4534-5516-6389-3477-5970-3537-150-178-1825-2503-3227-619-5716-2868-3057-777-1183-825-3822
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-20.9-19.6-18.8-22.1-27.6-31.3-17.1-29.8-17.5-0.8-1.0-10.7-14.1-18.6-3.4-31.0-14.7-16.9-4.4-7.3-5.1-24.5

Proceeds From Issuance Of Long Term Debt

Repayments Of Long Term Debt

us-gaap:RepaymentsOfLongTermDebt



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value11181533100264590187532146516571017562113038
Percentage of RepaymentsOfLongTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of LongTermDebtAndCapitalLeaseObligations0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Payments For Repurchase Of Common Stock

us-gaap:PaymentsForRepurchaseOfCommonStock



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value171142616282486220638084711444815334223893008962198274324151192774067435383
Percentage of PaymentsForRepurchaseOfCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0

Repayments Of Long Term Debt

us-gaap:RepaymentsOfLongTermDebt



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value11181533100264590187532146516571017562113038
Percentage of RepaymentsOfLongTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of LongTermDebtAndCapitalLeaseObligations0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Debt Instrument Interest Rate Stated Percentage

Effective Income Tax Rate Continuing Operations

us-gaap:EffectiveIncomeTaxRateContinuingOperations



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value0.11-0.025999999999999995-0.0310.0320.152-0.025999999999999995-0.0279999999999999970.2030.72100000000000010.2070.189-0.009000000000000008-0.0060000000000000050.225-0.021000000000000020.046000000000000010.051999999999999990.1290.1790.2250.2290.279
Percentage of EffectiveIncomeTaxRateContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

Share Based Compensation

us-gaap:ShareBasedCompensation



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value263160245314258156242268204229205203270204146206242198194173152157
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Liabilities

Deferred Tax Assets Net

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits



Period End2020-03-292019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value32003853332631513041308024652729305426992307240319781653
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:BalanceSheetLocation

jnj:AccruedTaxesOnIncome



Period End2020-03-292019-12-29
Value200900
Percentage of UnrecognizedTaxBenefits6.223.4

Deferred Tax Assets Valuation Allowance

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

Cash And Cash Equivalents Period Increase Decrease

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents



Period End2020-03-292019-12-292019-09-292019-03-312018-12-302018-09-302017-12-312017-01-01
Value1553017305162491473418107160561782418972
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CostOfGoodsSoldPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.3410.3310.3380.330.3240.3330.3310.3510.3090.3030.3080.2890.3050.3050.3010.3040.2920.310.3010.3040.3070.3170.3280.3120.3040.3170.3120.295
Percentage of CostOfGoodsSoldPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value5-47-9-1617626107
Percentage of EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value152327613362183
Percentage of EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod300.0-48.9-300.0-37.57.4138.5210.01185.7

jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue



Period End2020-03-292019-03-31
Value-97732
Percentage of FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue100.0100.0

jnj:GrossProfitPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.6590.6690.6620.670.6760.6670.6690.6490.6910.6970.6920.7110.6950.6950.6990.6960.7080.690.6990.6960.6930.6830.6720.6880.6960.6830.6880.705
Percentage of GrossProfitPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.3150.0790.3420.2210.2170.2390.2740.2440.2520.3140.2960.2650.3030.2410.3230.3210.3690.2890.2990.2090.2680.2430.2110.1240.3130.2570.2060.279
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IncomeTaxExpenseBenefitPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.035-0.0060.0690.0340.0240.0490.0560.0520.0490.0650.0560.0490.0570.0450.0690.0720.1120.0670.0380.0390.0540.0430.0570.0390.0710.0570.0390.064
Percentage of IncomeTaxExpenseBenefitPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:InterestExpensePercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.0010.0020.0040.0050.0120.0120.0130.0120.0120.0120.010.0110.0090.0070.0070.0080.0070.0070.0080.0060.0070.0070.0080.0090.0090.0080.0080.007
Percentage of InterestExpensePercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:InvestmentIncomeInterestPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-0.003-0.004-0.004-0.005-0.009-0.006-0.006-0.004-0.006-0.007-0.005-0.005-0.005-0.002-0.001-0.001-0.001-0.001-0.001-0.001-0.001-0.0010.0010.0010.0010.0010.0010.001
Percentage of InvestmentIncomeInterestPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:NetIncomeAttributableToParentPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-02
Value0.280.0850.2730.1870.1930.190.2180.1920.2030.2490.240.2160.2460.1960.2540.2490.2570.2220.2610.170.2140.20.1740.0850.2420.2
Percentage of NetIncomeAttributableToParentPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value6065727656
Percentage of OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax100.00.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value-2011174-142-142-176630-192-190-192
Percentage of OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherNonOperatingIncomeExpensePercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-0.0330.203-0.082-0.0010.00.0170.003-0.0120.031-0.009-0.0020.03-0.0020.025-0.053-0.02-0.0730.0110.0050.0540.0090.030.005-0.1220.0380.019-0.0130.001
Percentage of OtherNonOperatingIncomeExpensePercentToSales100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PercentageChangeInOperatingIncomeLoss



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-03
Value0.472-0.6280.416-0.193-0.0770.047-0.017-0.093-0.0320.0530.281-0.146-0.05-0.3950.020.0280.8570.1740.2730.021.355-0.155-0.177-0.2490.0850.066-0.192
Percentage of PercentageChangeInOperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ConsolidationItems

us-gaap:OperatingSegments



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value0.451-0.6080.378-0.211-0.0910.042-0.005-0.072-0.0260.0610.259-0.137-0.059-0.3790.025
Percentage of PercentageChangeInOperatingIncomeLoss95.696.890.9109.3118.289.429.477.481.2115.192.293.8118.095.9125.0

us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, jnj:Consumer



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value0.0390.28-0.510.352-0.4190.26-0.0810.2930.1520.053-0.1630.801-0.1210.993-0.549
Percentage of PercentageChangeInOperatingIncomeLoss8.3-44.6-122.6-182.4544.2553.2476.5-315.1-475.0100.0-58.0-548.6242.0-251.4-2745.0

us-gaap:OperatingSegments, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value0.3530.0991.025-0.052-0.084-0.1980.01-0.0940.056-0.0080.828-0.407-0.29-0.754-0.07
Percentage of PercentageChangeInOperatingIncomeLoss74.8-15.8246.426.9109.1-421.3-58.8101.1-175.0-15.1294.7278.8580.0190.9-350.0

us-gaap:OperatingSegments, jnj:Pharmaceutical



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value0.645-0.2530.007-0.3640.0070.0690.001-0.137-0.0740.0950.211-0.1060.129-0.1590.188
Percentage of PercentageChangeInOperatingIncomeLoss136.740.31.7188.6-9.1146.8-5.9147.3231.2179.275.172.6-258.040.3940.0

jnj:PercentageChangeInSalesByGeographicArea



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.0330.019-0.0130.0010.0360.1060.1260.1030.0190.0160.0420.0390.006-0.074-0.088-0.0410.0510.0910.0350.0310.0850.0850.065-0.007-0.0020.0680.0830.035
Percentage of PercentageChangeInSalesByGeographicArea100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementGeographical

country:US



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-02
Value0.0560.012-0.0220.0180.0360.0940.0610.0970.0160.0060.0670.0740.072-0.006-0.0240.0590.1160.1490.0220.0170.080.1120.134-0.012-0.051-0.037
Percentage of PercentageChangeInSalesByGeographicArea169.763.2169.21800.0100.088.748.494.284.237.5159.5189.71200.08.127.3-143.9227.5163.762.954.894.1131.8206.2171.42550.0-54.4

jnj:AsiaPacificAfrica



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value-0.0310.0730.0340.0230.0670.1350.2010.0850.0320.0310.0540.017-0.007-0.093-0.064-0.0980.0090.0270.036-0.0360.041
Percentage of PercentageChangeInSalesByGeographicArea-93.9384.2-261.52300.0186.1127.4159.582.5168.4193.8128.643.6-116.7125.772.7239.017.629.7102.9-116.148.2

jnj:WesternHemisphereExcludingUS



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value-0.001-0.04-0.055-0.041-0.0120.0270.0780.124-0.0280.092-0.0460.027-0.188-0.196-0.194-0.033-0.012-0.022-0.0490.010.102
Percentage of PercentageChangeInSalesByGeographicArea-3.0-210.5423.1-4100.0-33.325.561.9120.4-147.4575.0-109.569.2-3133.3264.9220.580.5-23.5-24.2-140.032.3120.0

srt:Europe



Period End2020-03-292019-09-292019-06-302019-03-31
Value0.0470.01-0.016-0.039
Percentage of PercentageChangeInSalesByGeographicArea142.452.6123.1-3900.0

jnj:PercentageChangeInSalesBySegmentOfBusiness



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-03
Value0.0330.0040.019-0.0130.001-0.020999999999999990.0360.1060.1260.0170.1030.0190.0160.0420.0390.006-0.074-0.088-0.0410.0510.0910.0350.0310.0850.0850.065-0.007-0.0020.0680.083
Percentage of PercentageChangeInSalesBySegmentOfBusiness100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-03
Value3323741173699446931866208402936591945843763584625861123880185
Percentage of ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Proceedsfromcreditsupportagreements



Period End2020-03-292019-03-31
Value17430
Percentage of Proceedsfromcreditsupportagreements100.00.0

jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.1250.1250.130.1430.1230.1270.120.1310.1210.1160.1220.1220.1150.1260.120.1090.110.1030.1010.1160.1090.1020.1130.1070.1020.1110.1130.108
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ResearchAndDevelopmentInProcessPercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-04-012017-10-012017-07-022016-10-022016-07-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-03
Value0.00.0-0.0220.0440.0560.00.00.00.00.0020.0010.00.00.00.00.0010.010.00.0040.040.0260.00.00.0
Percentage of ResearchAndDevelopmentInProcessPercentToSales0.00.0100.0100.0100.00.00.00.00.0100.0100.00.00.00.00.0100.0100.00.0100.0100.0100.00.00.00.0

jnj:Restructuringchargepercenttosales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-29
Value0.0030.0040.0020.0020.0040.0030.0020.0030.0010.0050.0030.0060.0070.00.00.0
Percentage of Restructuringchargepercenttosales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0

jnj:SellingGeneralAndAdministrativeExpensePercentToSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.2510.260.270.2610.2730.2750.2630.2750.280.2660.2680.280.2680.2970.3030.2790.2960.2810.2860.3020.3010.2980.3060.3010.3110.3270.3140.313
Percentage of SellingGeneralAndAdministrativeExpensePercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value89-18310299-2968990-2879494889910892113113-5101109118107115135141104-117127131-107118139-155
Percentage of SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:AdjustmentForAmortization

us-gaap:OperatingSegments, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-02
Value200200200200300300300300300200
Percentage of AdjustmentForAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, jnj:Pharmaceutical



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-02
Value800800800800700800800700200100
Percentage of AdjustmentForAmortization400.0400.0400.0400.0233.3266.7266.7233.366.750.0

us-gaap:AmortizationOfIntangibleAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-01
Value1100120011001100110011001100110011001114329282293307312365335347351335205
Percentage of AmortizationOfIntangibleAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount



Period End2020-03-292019-09-292019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value101900170000000205750515193866855
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.00.00.0100.00.00.00.00.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AssetImpairmentCharges



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-07-012012-04-01
Value11773076913321199048637823561101518713537697170
Percentage of AssetImpairmentCharges100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.00.0

us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1



Period End2020-03-292019-12-292019-03-312018-12-30
Value-9832206
Percentage of BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1100.0100.00.0100.0

us-gaap:BusinessAcquisition

jnj:AurisHealth



Period End2020-03-29
Value-983
Percentage of BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1100.0

us-gaap:BusinessAcquisition, us-gaap:IncomeStatementLocation

jnj:AurisHealth, us-gaap:OtherIncome



Period End2020-03-29
Value-1000
Percentage of BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1101.7

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect



Period End2020-03-292019-12-292019-03-312018-12-30
Value-17751056-33732051
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0

us-gaap:CommonStockDividendsPerShareCashPaid



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value0.950.95000000000000020.950.950.90.89999999999999990.90.90.840.83999999999999990.840.840.80.80.80.750.750.750.70.69999999999999970.70.70.660.660.660.610.610.610.570.570.570.540.540.540.49
Percentage of CommonStockDividendsPerShareCashPaid100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredIncomeTaxExpenseBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value54-350-1432-332-3621900338442813-27393-51-261545144-29698495365557-4960
Percentage of DeferredIncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value-36-32-32-33-32-31-31-31-30-35-34-35-34-33-34
Percentage of DefinedBenefitPlanAmortizationOfGainsLosses100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value-223-144-145-146-144-211-213-213-215-153-154-150-152-123-124
Percentage of DefinedBenefitPlanAmortizationOfGainsLosses619.4450.0453.1442.4450.0680.6687.1687.1716.7437.1452.9428.6447.1372.7364.7

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value-8-8-7-8-8-8-7-8-8-7-8-8-7-9-8
Percentage of DefinedBenefitPlanAmortizationOfPriorServiceCostCredit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value01111110101102-1
Percentage of DefinedBenefitPlanAmortizationOfPriorServiceCostCredit-0.0-12.5-14.3-12.5-12.5-12.5-14.3-0.0-12.5-0.0-12.5-12.5-0.0-22.212.5

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value212122122121211
Percentage of DefinedBenefitPlanExpectedReturnOnPlanAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value614580578581583548550554560513514509505490493
Percentage of DefinedBenefitPlanExpectedReturnOnPlanAssets30700.058000.028900.058100.029150.027400.055000.027700.028000.051300.025700.050900.025250.049000.049300.0

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanInterestCost

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value334746464636373837404040393939
Percentage of DefinedBenefitPlanInterestCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value240274273274275248247249252234232231230232233
Percentage of DefinedBenefitPlanInterestCost727.3583.0593.5595.7597.8688.9667.6655.3681.1585.0580.0577.5589.7594.9597.4

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value131139137139136124127127124129126128125118119
Percentage of DefinedBenefitPlanNetPeriodicBenefitCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value1942441121251122732182172151981411271289793
Percentage of DefinedBenefitPlanNetPeriodicBenefitCost148.1175.581.889.982.4220.2171.7170.9173.4153.5111.999.2102.482.278.2

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value-19-704-81-3002-16-210-6-4
Percentage of DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.0100.00.0100.0100.0

us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanServiceCost

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value726968696867676867626262615655
Percentage of DefinedBenefitPlanServiceCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PensionPlansDefinedBenefit



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-03
Value326335275277276358307309309308266255251224226
Percentage of DefinedBenefitPlanServiceCost452.8485.5404.4401.4405.9534.3458.2454.4461.2496.8429.0411.3411.5400.0410.9

us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation

us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings

us-gaap:CrossCurrencyInterestRateContract, us-gaap:FairValueHedging, jnj:InterestIncomeExpenseNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value4042393938292520
Percentage of DerivativeExcludedComponentGainLossRecognizedInEarnings100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation

us-gaap:DerivativeGainLossOnDerivativeNet

us-gaap:ForeignExchangeContract, us-gaap:Nondesignated, jnj:OtherIncomeExpenseNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value89-43-13-50-38-4549-53-19-27-1263
Percentage of DerivativeGainLossOnDerivativeNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation

us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred

us-gaap:CrossCurrencyInterestRateContract, us-gaap:CashFlowHedging, jnj:InterestIncomeExpenseNet



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value988964553432
Percentage of DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred100.0100.0100.0100.0100.0100.0

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, jnj:OtherIncomeExpenseNet



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value-2126-3-10
Percentage of DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred-2.01.13.110.9-8.8-31.2

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:CostOfSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value-173-77-101-359776
Percentage of DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred-176.5-86.5-157.8-63.6285.3237.5

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:ResearchAndDevelopmentExpense



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value-110191136-13910-14
Percentage of DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred-112.22147.256.2-252.729.4-43.8

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:Sales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value9-8-14-21417
Percentage of DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred9.2-9.0-21.9-38.211.853.1

us-gaap:DividendsCommonStockCash



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value250525002499252223962411241524152253
Percentage of DividendsCommonStockCash100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value250525002499252223962411241524152253
Percentage of DividendsCommonStockCash100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-237-1161617-32-391044011081-299-492-391-119-91-55-45-1535770-53
Percentage of EffectOfExchangeRateOnCashAndCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:EquityFairValueAdjustment

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value-327332-91149143-212-10-27
Percentage of EquityFairValueAdjustment100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value-33-10-5-2746-6-20
Percentage of EquityFairValueAdjustment10.1-3.05.5-18.12.8-2.860.074.1

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases



Period End2020-03-292019-03-31
Value10623
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases100.0100.0

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements



Period End2020-03-292019-12-292019-03-312018-12-30
Value60-790-12
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements100.0100.00.0100.0

us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-29
Value02946200772774007800240996384719003320580
Percentage of GainLossOnSalesOfAssetsAndAssetImpairmentCharges0.0100.0100.0100.0100.0100.00.00.0100.00.0100.0100.0100.0100.0100.0100.00.0100.00.0

us-gaap:GoodwillAcquiredDuringPeriod



Period End2020-03-292019-03-312018-04-012017-04-022016-04-032015-03-292014-03-302013-03-312012-04-012011-04-03
Value15711995320501860790474
Percentage of GoodwillAcquiredDuringPeriod100.0100.0100.0100.0100.0100.00.0100.00.0100.0

us-gaap:StatementBusinessSegments

jnj:Consumer



Period End2020-03-292019-03-312018-04-012017-04-022016-04-032015-03-292014-03-302013-03-312012-04-01
Value01176010000700
Percentage of GoodwillAcquiredDuringPeriod0.098.10.00.50.00.00.088.60.0

jnj:MedicalDevices



Period End2020-03-292019-03-312018-04-012017-04-022016-04-032015-03-29
Value15623532040122
Percentage of GoodwillAcquiredDuringPeriod99.41.9100.099.5100.025.6

jnj:Pharmaceutical



Period End2020-03-292019-03-312018-04-012017-04-022016-04-032015-03-292014-03-302013-03-312012-04-01
Value1000064000
Percentage of GoodwillAcquiredDuringPeriod0.60.00.00.00.074.40.00.00.0

us-gaap:GoodwillOtherIncreaseDecrease



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-31
Value-325276-364195-202-1221278-810237
Percentage of GoodwillOtherIncreaseDecrease100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementBusinessSegments

jnj:Consumer



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-31
Value-223144-21767-116-69-72427
Percentage of GoodwillOtherIncreaseDecrease68.652.259.634.457.456.6-0.5-3.011.4

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-31
Value-615-2012-11-41215-981190
Percentage of GoodwillOtherIncreaseDecrease1.85.45.56.25.43.395.1121.180.2

jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-31
Value-96117-127116-75-497014720
Percentage of GoodwillOtherIncreaseDecrease29.542.434.959.537.140.25.5-18.18.4

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value65094218164770414422312244234973548125604790474855754324528149045294375841225741557527036810562654242750366747934261310035952035504531841113422451022284219422062802604424542634643
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-2523178727171389-18333220780-16862386-2030-2333645248-24511782-232409-1004-1459-1331-1127-1651
Percentage of IncreaseDecreaseInAccountsPayableAndAccruedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsReceivable



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value812-376329493-1571455147933396389-276421765-152-185158426434215609529
Percentage of IncreaseDecreaseInAccountsReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherOperatingAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-271973-781374488-629637907-144573802-384-1164562-370-6364121526087549701088
Percentage of IncreaseDecreaseInOtherOperatingAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value-329-6182098113-168-687-9915959297420-385450151021-1847868311-428-192891111696
Percentage of IncreaseDecreaseInOtherOperatingLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value00000000001111122220223333333333333
Percentage of IncrementalCommonSharesAttributableToConversionOfDebtSecurities100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value126117140136140127139139143141140146144129151154148154163154162175181138165168138149175193
Percentage of IncrementalCommonSharesAttributableToShareBasedPaymentArrangements100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InvestmentIncomeInterest



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value6781898899196175126114857410512197888332241917181418181721151417171821134327
Percentage of InvestmentIncomeInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementBusinessSegments

us-gaap:LitigationSettlementExpense

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-312017-10-012017-07-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value10010002001001000070063910040055570106409134
Percentage of LitigationSettlementExpense100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312017-12-312016-04-032015-09-27
Value10004000100300171360
Percentage of LitigationSettlementExpense100.00.00.050.0300.02.7128.30.0

us-gaap:LitigationCase, us-gaap:LitigationStatus

us-gaap:LossContingencyDamagesAwardedValue

jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPI, us-gaap:JudicialRuling



Period End2020-03-292019-12-29
Value5720
Percentage of LossContingencyDamagesAwardedValue100.00.0

jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPI, us-gaap:SettledLitigation



Period End2020-03-29
Value465
Percentage of LossContingencyDamagesAwardedValue81.3

us-gaap:LitigationStatus

us-gaap:JudicialRuling



Period End2020-01-312020-03-292019-12-29
Value63448000
Percentage of LossContingencyDamagesAwardedValue60.10.00.0

us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-03
Value93924821636631683267582505485250023318382910016802049
Percentage of NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.00.00.0100.00.0100.0

us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-03
Value1136367117459021541712119443525070147618623050018602245
Percentage of NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.00.00.0100.00.0100.0

us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-03
Value197119-99927471-493737-62398201243241400180196
Percentage of NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.00.00.0100.00.0100.0

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-1519739-667350-258200-151-219062399359843395-94-295879-1069903-2563-2102-2400-2361371278-116-12101485-1619823-17904141373
Percentage of OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-01
Value2-10101-100-37-8533-90-13144-138-9017258146-36142759-287177-266-38106
Percentage of OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax100.0100.00.0100.00.0100.0100.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value970-3360-20696-16414
Percentage of OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value-256-916-5526-444
Percentage of OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value832192286-302262-61-164
Percentage of OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value-138195526-96166103-178
Percentage of OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation

us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax

us-gaap:CrossCurrencyInterestRateContract, us-gaap:CashFlowHedging, jnj:InterestIncomeExpenseNet



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value62515982593519
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax100.0100.0100.0100.0100.0100.0

us-gaap:CrossCurrencyInterestRateContract, us-gaap:FairValueHedging, jnj:InterestIncomeExpenseNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value4042393938292520
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax6.40.024.547.664.40.071.410.50.0

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, jnj:OtherIncomeExpenseNet



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value-365-3-13-13
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax-5.83.1-3.7-22.0-2.915.8

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:CostOfSales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value302-197-50-296192-57
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax48.3-123.9-61.0-501.7548.6-300.0

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:ResearchAndDevelopmentExpense



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value-110193918-110-421
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax-17.61219.522.0-186.4-11.4110.5

us-gaap:ForeignExchangeContract, us-gaap:CashFlowHedging, us-gaap:Sales



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value11-230-615-49
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax1.8-14.50.0-10.242.9-257.9

us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value46162-5771-50306
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk

us-gaap:CrossCurrencyInterestRateContract



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value827152-57370-7537
Percentage of OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax1797.893.8100.0521.1150.012.1

us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value-4669-94106-61315104-346163
Percentage of OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-01
Value-352-358-564548-295-575130-2169823-4524871288379-8-316774-8071246-2578-5340-2375-3622151464-121-8791279-16641092
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-02
Value195-1175136137169-565186186-527119
Percentage of OtherComprehensiveIncomeLossNetOfTax-55.4328.2-24.125.0-57.398.3143.122.6116.631.4

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-31
Value97079-3360-206
Percentage of OtherComprehensiveIncomeLossNetOfTax-275.6-22.15.910.969.8

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-02
Value2-10101-10-37-90
Percentage of OtherComprehensiveIncomeLossNetOfTax-0.60.3-0.00.2-0.0-0.2-0.80.08.2-23.7

us-gaap:AccumulatedOtherComprehensiveIncome



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-04-02
Value-352-358-564548-295-575130-2169823-452379
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AccumulatedTranslationAdjustment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-02
Value-1519739-667350-258200-15162399395
Percentage of OtherComprehensiveIncomeLossNetOfTax431.5-206.4118.363.987.5-34.8-116.275.7-21.9104.2

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-01
Value-1951175-136-137-169565-186-185-186527-120-118-119-98-95-102-154-153-1543595-96-97-94-130-131-131-94-95-94
Percentage of OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-01
Value56-29134341159-52-51-5298-61-60605156487575761417464746686769494949
Percentage of OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-01
Value00000-210046991417942128246245741000289030
Percentage of OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax0.00.00.00.00.0100.0100.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0100.00.0100.00.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value2-1010-1000914478929156-56-44196115150-351427592177-263-38107-108322113
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.00.0100.00.0100.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax



Period End2020-03-292019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-100000-20-451748777744892327819715321559514420575917112
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax100.00.00.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsForProceedsFromOtherInvestingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value25728-71-979641615-2117-112401115253138142579
Percentage of PaymentsForProceedsFromOtherInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan

us-gaap:PaymentsForRestructuring

us-gaap:EmployeeSeverance, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-02
Value676166161625
Percentage of PaymentsForRestructuring100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherRestructuring, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-02
Value999896108170147122196118
Percentage of PaymentsForRestructuring1650.01400.01600.010800.02833.32450.0762.51225.0472.0

us-gaap:RestructuringPlan

jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-04-02
Value105105102109176153138143
Percentage of PaymentsForRestructuring1750.01500.01700.010900.02933.32550.0862.5572.0

us-gaap:PaymentsOfOrdinaryDividends



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value2505250024992522239624112415225322562171206920762079194619561967197818671706156514801350
Percentage of PaymentsOfOrdinaryDividends100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value93924821636631683267582505485250023318382910016802049772
Percentage of PaymentsToAcquireBusinessesNetOfCashAcquired100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.00.00.0100.00.0100.0100.0

us-gaap:BusinessAcquisition

jnj:Bermekimab



Period End2020-03-29
Value800
Percentage of PaymentsToAcquireBusinessesNetOfCashAcquired85.2

us-gaap:RetirementPlanSponsorLocation

us-gaap:PensionContributions

country:US



Period End2020-03-292019-12-292019-09-292019-06-302019-03-31
Value23427202121
Percentage of PensionContributions100.0100.0100.0100.0100.0

us-gaap:ForeignPlan



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-31
Value9324887943399562
Percentage of PensionContributions39.175.940.038.1376.20.00.00.00.0

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-03
Value-41241562101-381-92125-163-25000-50000030-1600
Percentage of ProceedsFromPaymentsForOtherFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0100.00.00.00.00.0100.0100.00.0

us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value1544928327637149531274193416068994914573389779605095436354414540772800660048972440
Percentage of ProceedsFromSaleMaturityAndCollectionsOfInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromSaleOfProductiveAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value1716285276525323082520110631254271083110150390853835106358121102
Percentage of ProceedsFromSaleOfProductiveAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromShortTermDebt



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value10-109133213401326-38917199510834355891234-1039139027847515473644715
Percentage of ProceedsFromShortTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProvisionForDoubtfulAccounts



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value22-5-164-3-2813-20-42-13-1-326-2126-17-12-25-1142-1678
Percentage of ProvisionForDoubtfulAccounts100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RepaymentsOfShortTermDebt



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-04-022016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-03-312012-04-012011-04-032010-04-04
Value181375-416114-6824843941954172585152193-446647-2091275704179027443043
Percentage of RepaymentsOfShortTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value25803232259926662858322425082639240436352574228520602178226420132154212918992635202320051831204219461784192317661645177318821738165716481557
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ResearchAndDevelopmentInProcess



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-12-312017-10-012017-07-022016-10-022016-07-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012011-10-022011-07-03
Value0000890011260408000292141000156041829417806459679429000
Percentage of ResearchAndDevelopmentInProcess0.00.00.00.0100.00.0100.00.0100.00.00.00.0100.0100.0100.00.00.0100.00.0100.0100.0100.0100.00.0100.0100.0100.0100.00.00.00.0

us-gaap:RestructuringCharges



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292012-07-012012-01-012011-07-032011-01-022010-01-03
Value5825169573622788574214469118562114120000065658911861200
Percentage of RestructuringCharges100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.0100.0100.0100.0100.0

us-gaap:IncomeStatementLocation, us-gaap:RestructuringPlan

jnj:OtherIncomeExpenseNet, jnj:SupplyChain



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value45833947313421
Percentage of RestructuringCharges77.633.156.582.586.138.636.8

us-gaap:CostOfSales, jnj:SupplyChain



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value15192038231425
Percentage of RestructuringCharges25.97.629.066.763.915.943.9

us-gaap:RestructuringCharges, jnj:SupplyChain



Period End2020-03-29
Value58
Percentage of RestructuringCharges100.0

us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan

jnj:AssetWriteoff, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-04-02
Value112038233251537
Percentage of RestructuringCharges19.029.066.763.914.158.011.943.5

us-gaap:OtherRestructuring, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-012017-04-02
Value10710810467195139102124
Percentage of RestructuringCharges184.5156.5182.5186.185.9158.0242.9145.9

us-gaap:RestructuringPlan

jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-10-012017-07-022017-04-02
Value11812814290227101117107187128161
Percentage of RestructuringCharges203.4185.5249.1250.0100.0114.8205.3254.8271.01163.6189.4

jnj:SupplyChain



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-01
Value118240128142908959
Percentage of RestructuringCharges203.495.6185.5249.1250.0101.1103.5

us-gaap:StatementBusinessSegments

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-03
Value10020010010010062200100100284200100161298109141137590
Percentage of RestructuringCharges172.479.7144.9175.4277.827.3227.3175.4238.1197.2289.9909.1189.40.0175.8123.7114.20.0

us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan

us-gaap:RestructuringReserveSettledWithoutCash2

jnj:AssetWriteoff, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value1120382332515
Percentage of RestructuringReserveSettledWithoutCash2100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherRestructuring, jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value17000000
Percentage of RestructuringReserveSettledWithoutCash2154.50.00.00.00.00.00.0

us-gaap:RestructuringPlan

jnj:MedicalDevices



Period End2020-03-292019-09-292019-06-302019-03-312018-12-302018-09-302018-04-01
Value2820382332515
Percentage of RestructuringReserveSettledWithoutCash2254.5100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value595536363683351629560409351
Percentage of StockIssuedDuringPeriodValueTreasuryStockReissued100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value-1049-9217974-919-281-24245-1051
Percentage of StockIssuedDuringPeriodValueTreasuryStockReissued-176.3-17.249.310.8-261.8-44.7-4.359.9-299.4

us-gaap:TreasuryStock



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value164462818460912709105841641402
Percentage of StockIssuedDuringPeriodValueTreasuryStockReissued276.3117.250.789.2361.8144.7104.340.1399.4

us-gaap:TreasuryStockValueAcquiredCostMethod



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value171142616282486220638084711451444
Percentage of TreasuryStockValueAcquiredCostMethod100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StatementEquityComponents

us-gaap:TreasuryStock



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value171142616282486220638084711451444
Percentage of TreasuryStockValueAcquiredCostMethod100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:UnrealizedGainLossOnSecurities

us-gaap:OperatingSegments, jnj:Pharmaceutical



Period End2020-03-292019-12-292019-09-292019-06-302019-03-31
Value300400-100200100
Percentage of UnrealizedGainLossOnSecurities100.0100.0100.0100.0100.0

jnj:AccruedRebatesReturnsAndPromotions



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1160810883109771043395239380868487177956721069456319545154035181525952595440533848404697401042083972346333083465313829102969304029602865263728952933285825122028
Percentage of AccruedRebatesReturnsAndPromotions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProductOrService

jnj:ProductLiabilityContingencyNumberOfClaimant

jnj:Asr



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-30
Value940.01100.01400.01500.01700.01800.02000.02000.02000.02000.02000.02000.02000.02000.02900.02900.03000.05300.06300.06500.09200.011200.012300.012700.012500.012340.012140.011500.011100.010750.0
Percentage of ProductLiabilityContingencyNumberOfClaimant100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Invokana



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value300.0400.0700.01000.01000.01050.01100.01100.01100.01100.01100.0800.0
Percentage of ProductLiabilityContingencyNumberOfClaimant31.936.450.066.758.858.355.055.055.055.055.040.0

jnj:PelvicMeshes



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-30
Value16500.017600.019800.024800.029500.034800.037400.054000.054000.053600.054300.055500.055800.054800.053400.050100.049300.046700.044400.040000.038500.036600.035600.033000.031500.028810.023040.012250.06700.04000.0
Percentage of ProductLiabilityContingencyNumberOfClaimant1755.31600.01414.31653.31735.31933.31870.02700.02700.02680.02715.02775.02790.02740.01841.41727.61643.3881.1704.8615.4418.5326.8289.4259.8252.0233.5189.8106.560.437.2

jnj:Physiomesh



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value3500.03300.03100.02900.02500.02100.01500.0
Percentage of ProductLiabilityContingencyNumberOfClaimant372.3300.0221.4193.3147.1116.775.0

jnj:PinnacleAcetabularCupSystem



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-30
Value9500.010300.010500.010500.010500.010500.010400.010300.010200.010000.09900.09700.09600.09400.09300.09100.08900.08700.08300.08000.07600.07300.06900.06600.06000.05560.05160.04450.04000.03300.0
Percentage of ProductLiabilityContingencyNumberOfClaimant1010.6936.4750.0700.0617.6583.3520.0515.0510.0500.0495.0485.0480.0470.0320.7313.8296.7164.2131.7123.182.665.256.152.048.045.142.538.736.030.7

jnj:Risperdal



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-30
Value10900.011900.013600.013400.013100.013400.013000.013500.014000.013700.013900.013800.016900.018500.015400.013000.012500.010700.05400.04200.02400.01200.01000.0670.0580.0500.0490.0490.0440.0425.0
Percentage of ProductLiabilityContingencyNumberOfClaimant1159.61081.8971.4893.3770.6744.4650.0675.0700.0685.0695.0690.0845.0925.0531.0448.3416.7201.985.764.626.110.78.15.34.64.14.04.34.04.0

jnj:Talc



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-10-012017-07-02
Value19400.017900.016800.015500.014200.013000.011700.010600.09100.05500.04800.0
Percentage of ProductLiabilityContingencyNumberOfClaimant2063.81627.31200.01033.3835.3722.2585.0530.0455.0275.0240.0

jnj:Xarelto



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-28
Value24600.029000.030700.031700.027300.025600.025500.024800.026300.022900.021400.020000.018400.016900.015600.013900.07100.05000.03000.01100.0
Percentage of ProductLiabilityContingencyNumberOfClaimant2617.02636.42192.92113.31605.91422.21275.01240.01315.01145.01070.01000.0920.0845.0537.9479.3236.794.347.616.9

us-gaap:AccruedIncomeTaxesNoncurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-01-01
Value74027444749375438074824285378647945384720
Percentage of AccruedIncomeTaxesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:AccruedLiabilitiesCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value838497159004829779467601604463946535730458976076526256355283565049965411506253195575655361887178771076856921664669047299649865334369460841364405409341004625
Percentage of AccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value234226227251244248281269281291332292246252267270278268260266237275262295310333429421400466451434419361315327339340333
Percentage of AllowanceForDoubtfulAccountsReceivableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-31
Value102941941948519502208180917430
Percentage of AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

us-gaap:AvailableforsaleSecurities



Period End2020-03-292019-09-292019-06-30
Value411
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-292019-09-292019-06-30
Value411
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

us-gaap:AvailableforsaleSecurities



Period End2020-03-29
Value2
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-29
Value2
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.0

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-29
Value0.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax0.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis

us-gaap:AvailableforsaleSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value567143684326276646739734
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis100.0100.0100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value253266272265261260
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis4.56.16.39.65.62.7

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value541841024050250144129474
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis95.593.993.690.494.497.3

us-gaap:AvailableForSaleSecuritiesDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value567343684327276746739734
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302017-12-312017-01-012016-01-032014-12-28
Value56734368432727674673973453101208783160
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0100.0100.00.00.00.00.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableforsaleSecurities



Period End2020-03-292019-09-292019-06-302019-03-31
Value5673432727674673
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-09-292019-06-302019-03-31
Value251272265261
Percentage of AvailableForSaleSecuritiesDebtSecurities4.46.39.65.6

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-292019-09-292019-06-302019-03-31
Value5422405125024412
Percentage of AvailableForSaleSecuritiesDebtSecurities95.693.690.494.4

us-gaap:BusinessCombinationContingentConsiderationLiability



Period End2020-03-292019-12-292019-09-292019-06-302018-12-30
Value784171515961479335
Percentage of BusinessCombinationContingentConsiderationLiability100.0100.0100.0100.0100.0

us-gaap:BalanceSheetLocation

us-gaap:OtherCurrentLiabilities



Period End2020-03-292019-12-292019-09-292019-06-30
Value2584143109
Percentage of BusinessCombinationContingentConsiderationLiability3.24.99.07.4

us-gaap:OtherNoncurrentLiabilities



Period End2020-03-292019-12-292019-09-292019-06-302018-12-302017-12-31
Value165163114531370335600
Percentage of BusinessCombinationContingentConsiderationLiability21.095.191.092.6100.00.0

us-gaap:BalanceSheetLocation, us-gaap:BusinessAcquisition

us-gaap:OtherNoncurrentLiabilities, jnj:AurisHealth



Period End2020-03-292019-12-29
Value7591631
Percentage of BusinessCombinationContingentConsiderationLiability96.895.1

us-gaap:BusinessAcquisition

jnj:AurisHealth



Period End2020-03-292019-04-01
Value2002350
Percentage of BusinessCombinationContingentConsiderationLiability25.50.0

us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel3



Period End2020-03-292019-12-292019-09-292019-06-302018-12-30
Value784171515961479335
Percentage of BusinessCombinationContingentConsiderationLiability100.0100.0100.0100.0100.0

us-gaap:BusinessAcquisition

us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities

jnj:CizHoldingsCo.Ltd.



Period End2020-03-292019-12-292019-09-292019-06-30
Value400400400500
Percentage of BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities100.0100.0100.0100.0

jnj:VerbSurgicalInc.



Period End2020-03-29
Value300
Percentage of BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities75.0

us-gaap:BusinessAcquisition

us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

jnj:Bermekimab



Period End2020-03-29
Value800
Percentage of BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill100.0

jnj:VerbSurgicalInc.



Period End2020-03-29
Value400
Percentage of BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill50.0

us-gaap:DeferredIncomeTaxAssetsNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value753978197696764775337640
Percentage of DeferredIncomeTaxAssetsNet100.0100.0100.0100.0100.0100.0

us-gaap:DeferredIncomeTaxLiabilitiesNet



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value576659586526772573947506
Percentage of DeferredIncomeTaxLiabilitiesNet100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeAssetFairValueGrossLiability



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value2530841101343759242329029576
Percentage of DerivativeAssetFairValueGrossLiability100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value10084198162104271308356387
Percentage of DerivativeAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeFairValueOfDerivativeAsset



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value26309251211599696694598651463
Percentage of DerivativeFairValueOfDerivativeAsset100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeFairValueOfDerivativeLiability



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value8836521083930892872715778605
Percentage of DerivativeFairValueOfDerivativeLiability100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value2510902117957666357059335457243332027233436948084276010281027645404642706609752492521222466249457611489467338562
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk

us-gaap:ForeignExchangeContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value941209498251280551547351556418291222279319452791723976996534196431537482693480423213449241442604487321
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue37.523.242.243.642.296.792.299.297.296.590.981.683.586.494.293.995.194.997.082.848.567.176.179.192.297.681.295.996.496.896.798.999.695.0

us-gaap:InterestRateContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-29
Value1569693681325383194631615295055502851375231111208211169
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue62.576.857.856.457.83.37.80.82.83.59.118.416.513.65.86.14.95.13.017.251.532.923.9

us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:ForeignExchangeContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value941209498251280501551547351342556418291747222279319452791723976996534196431537482693480423213449241442
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue37.523.242.243.642.20.096.792.299.20.097.296.590.90.081.683.586.494.293.995.194.997.082.848.567.176.179.192.297.681.295.996.496.896.7

us-gaap:InterestRateContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292012-12-30
Value156969368132538316119463716152931505550285137523111120821116998
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue62.576.857.856.457.80.03.37.80.80.02.83.59.10.018.416.513.65.86.14.95.13.017.251.532.923.918.8

us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-03
Value2510902117957666366257059335434957243332077827233436948084276010281027645404642706609752492521222466249457611489
Percentage of DerivativeInstrumentsInHedgesAssetsAtFairValue100.0100.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value777619104587586667070728850877798494699178459965769412707595832761531591911912302628981102827104610241050120010881179
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk

us-gaap:ForeignExchangeContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value5304266354815714014712692924545765425695543584725521068751579266141133181163198252315403290452425646586
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue68.268.860.855.065.959.966.693.457.558.458.557.357.470.759.871.879.584.198.999.396.492.283.694.885.386.196.235.136.635.143.241.561.553.9

us-gaap:InterestRateContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-29
Value2471934103942952692361921027334530931421024118514220284101226
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue31.831.239.245.034.140.133.46.641.335.135.132.731.726.840.228.220.515.91.10.73.67.816.4

us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:ForeignExchangeContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value5304266354815715484014712693142924545767235425695543584725521068751579266141133181163198252315403290452
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue68.268.860.855.065.90.059.966.693.40.057.558.458.50.057.357.470.759.871.879.584.198.999.396.492.283.694.885.386.196.235.136.635.143.2

us-gaap:InterestRateContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292012-12-30
Value24719341039429529226923619152102733453823093142102411851422028410122610
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue31.831.239.245.034.10.040.133.46.60.041.335.135.10.032.731.726.840.228.220.515.91.10.73.67.816.43.8

us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-03
Value7776191045875866840670707288329508777984116294699178459965769412707595832761531591911912302628981102827104610241050
Percentage of DerivativeInstrumentsInHedgesLiabilitiesAtFairValue100.0100.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeLiabilities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value35266138109240267272357367
Percentage of DerivativeLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeLiabilityFairValueGrossAsset



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012017-12-31
Value531586945821652605443421238
Percentage of DerivativeLiabilityFairValueGrossAsset100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk

us-gaap:DerivativeNotionalAmount

us-gaap:ForeignExchangeContract



Period End2020-03-292019-12-29
Value4400045300
Percentage of DerivativeNotionalAmount100.0100.0

us-gaap:EmployeeRelatedLiabilitiesCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value216633542886229119863098284022551892295329002374183626762554216818302474232420751557275123332142174327942324200116312423212819111526232922632104177726422777
Percentage of EmployeeRelatedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-01-01
Value10529106639830991099059951937499891006610074968696879615
Percentage of EmployeeRelatedLiabilitiesCurrentAndNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EquitySecuritiesFvNi



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value8261148863963830511
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel1



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value8261148863963830511
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302017-12-31
Value694712699677698681510
Percentage of EquitySecuritiesWithoutReadilyDeterminableFairValueAmount100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue



Period End2020-03-292019-12-292019-09-292019-03-312018-12-302018-09-302017-12-312017-01-01
Value78417151596452335403600378
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization

jnj:PatentsAndTrademarks



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value138571315412158115001054897849077826775947223639555465226507650174974487947454687431742014700461445454291414637893647350634163317319631222976
Percentage of FiniteLivedIntangibleAssetsAccumulatedAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherIntangibleAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value9728946291208874858683238168791577487463729770536741651564116242606258165637547852485227507550464833487246454410421140303891356035173432
Percentage of FiniteLivedIntangibleAssetsAccumulatedAmortization70.271.975.077.281.485.190.095.7102.0103.3114.1127.2129.0128.3127.8125.5124.2122.6120.3126.9124.9111.2110.0111.0112.6117.5122.6120.9120.1118.0117.3111.4112.7115.3

us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsGross

jnj:PatentsAndTrademarks



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value3621436634361143658235963351943547834823359803642736342358041131110521108158633835182998298842884009074899191629190916489538878883288908874877881307947
Percentage of FiniteLivedIntangibleAssetsGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherIntangibleAssets



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value220842205621845218622176621334211762105921141202042024120048196531761517830177991784817583177391798517764179701825618827188091902718810185391850918755186461822786688716
Percentage of FiniteLivedIntangibleAssetsGross61.060.260.559.860.560.659.760.558.855.555.756.0173.8167.4164.9206.2213.7211.9213.8213.4211.5198.0203.0205.5204.7207.6210.1208.8209.6211.0210.1207.6106.6109.7

us-gaap:DerivativeInstrumentRisk

us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue

us-gaap:ForeignExchangeContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value120233223332858253856261428443356267029282323253727267518222329202819
Percentage of ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:ForeignExchangeContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value120233223333228582538385626341428443356267029282323253727267518222329
Percentage of ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue100.0100.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk

us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue

us-gaap:ForeignExchangeContract



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value106333855264571537231623362354139696351402649291566782327411934142739
Percentage of ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:ForeignExchangeContract, us-gaap:FairValueInputsLevel2



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value106333855263245715338723162573362354139696351402649291566782327411934
Percentage of ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue100.0100.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:HeldToMaturitySecurities

us-gaap:HeldtomaturitySecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value123511491913618125111066399538209
Percentage of HeldToMaturitySecurities100.0100.0100.0100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:HeldtomaturitySecurities, jnj:OtherReverseRepurchaseAgreements



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value473375241219350443479
Percentage of HeldToMaturitySecurities3.82.51.81.83.34.55.8

us-gaap:HeldtomaturitySecurities, us-gaap:BankTimeDeposits



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value765906691651533485932
Percentage of HeldToMaturitySecurities6.26.15.15.25.04.911.4

us-gaap:HeldtomaturitySecurities, us-gaap:Cash



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value2499263726672615277826192575
Percentage of HeldToMaturitySecurities20.217.719.620.926.126.331.4

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value213513231647264549200
Percentage of HeldToMaturitySecurities17.38.912.12.15.12.4

us-gaap:HeldtomaturitySecurities, us-gaap:MoneyMarketFunds



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value2424286414811368419533971763
Percentage of HeldToMaturitySecurities19.619.210.910.939.334.121.5

us-gaap:HeldtomaturitySecurities, us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value39656182701420682260
Percentage of HeldToMaturitySecurities32.145.456.119.427.5

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value904397093801900
Percentage of HeldToMaturitySecurities0.72.95.23.01.80.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain

us-gaap:HeldtomaturitySecurities



Period End2020-03-292019-09-292019-06-302018-09-30
Value1000000.00.00.00.0
Percentage of HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain100.00.00.00.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-09-292019-06-302018-09-30
Value1000000.00.00.00.0
Percentage of HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain100.00.00.00.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss

us-gaap:HeldtomaturitySecurities



Period End2020-03-292018-09-30
Value1000000.00.0
Percentage of HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss100.00.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292018-09-30
Value1000000.00.0
Percentage of HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss100.00.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:HeldToMaturitySecuritiesFairValue

us-gaap:HeldtomaturitySecurities



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value123511361812511106638209
Percentage of HeldToMaturitySecuritiesFairValue100.0100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:HeldtomaturitySecurities, jnj:OtherReverseRepurchaseAgreements



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value473241219350479
Percentage of HeldToMaturitySecuritiesFairValue3.81.81.83.35.8

us-gaap:HeldtomaturitySecurities, us-gaap:BankTimeDeposits



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value765691651533932
Percentage of HeldToMaturitySecuritiesFairValue6.25.15.25.011.4

us-gaap:HeldtomaturitySecurities, us-gaap:Cash



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value24992667261527782575
Percentage of HeldToMaturitySecuritiesFairValue20.219.620.926.131.4

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value21351647264549200
Percentage of HeldToMaturitySecuritiesFairValue17.312.12.15.12.4

us-gaap:HeldtomaturitySecurities, us-gaap:MoneyMarketFunds



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value24241481136841951763
Percentage of HeldToMaturitySecuritiesFairValue19.610.910.939.321.5

us-gaap:HeldtomaturitySecurities, us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value39656182701420682260
Percentage of HeldToMaturitySecuritiesFairValue32.145.456.119.427.5

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities



Period End2020-03-292019-09-292019-06-302019-03-312018-09-30
Value907093801900
Percentage of HeldToMaturitySecuritiesFairValue0.75.23.01.80.0

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1262511569111651126283039190922810356105861128311678116891046910331104251047810582104431027510399103101010587468724876887749138834483858553847889507998788379018116917278917675
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:BusinessAcquisition, us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

jnj:Bermekimab, jnj:PurchasedInProcessResearchAndDevelopment



Period End2020-03-29
Value800
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill6.3

jnj:VerbSurgicalInc., jnj:PurchasedInProcessResearchAndDevelopment



Period End2020-03-29
Value400
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill3.2

us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

jnj:PurchasedInProcessResearchAndDevelopment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-01-02
Value579646474290432313912253222634043473420145854620351234433383339334103420319132223195284213211117113411551504843829905957159418801849213
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill45.940.238.438.416.824.524.132.932.837.239.339.533.533.332.532.432.232.731.131.031.028.115.112.812.913.216.510.19.910.611.317.823.523.52.7

us-gaap:Trademarks



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value6829692268756939691269377002695271137082709370696957688870427085717270237084717771157263742576077634761976347501755676487521735661186034
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill54.159.861.661.683.275.575.967.167.262.860.760.566.566.767.567.667.867.368.969.069.071.984.987.287.186.883.589.990.189.488.782.276.576.5

us-gaap:InventoryFinishedGoodsNetOfReserves



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-01-02
Value54036071607960415828537654905362547553085992604657115007565555875283487649824953478045094951476844994042406538864073381739214463357434422845
Percentage of InventoryFinishedGoodsNetOfReserves100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-01-02
Value121311171094119811771114120211661200114011411138104695297495295793611981179111512141165125112001224134513321250141614081300142812061073
Percentage of InventoryRawMaterialsAndSuppliesNetOfReserves100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InventoryWorkInProcessNetOfReserves



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-01-02
Value22521832200020242081210919862282233923172388251521212185185919841930224120262166219024612303213623102612271426042368226224801934179816371460
Percentage of InventoryWorkInProcessNetOfReserves100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:MarketableSecuritiesCurrent



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-28
Value2494198216969026021580330857056547251025518434229352222823944259942464423667233151933118566
Percentage of MarketableSecuritiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableforsaleSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value13981258111890250215803308
Percentage of MarketableSecuritiesCurrent56.163.565.9100.083.4100.0100.0

us-gaap:HeldtomaturitySecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value1096724578010000
Percentage of MarketableSecuritiesCurrent43.936.534.10.016.60.00.0

us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value236251258245233250259
Percentage of MarketableSecuritiesCurrent9.512.715.227.238.715.87.8

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value1162100785665726913303049
Percentage of MarketableSecuritiesCurrent46.650.850.572.844.784.292.2

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities



Period End2020-03-292019-12-292019-09-292019-03-312018-09-30
Value10964344881000
Percentage of MarketableSecuritiesCurrent43.921.928.816.60.0

us-gaap:HeldtomaturitySecurities, us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase



Period End2020-03-29
Value0.0
Percentage of MarketableSecuritiesCurrent0.0

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities



Period End2020-03-292019-12-292019-09-29
Value029090
Percentage of MarketableSecuritiesCurrent0.014.65.3

us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:MarketableSecuritiesNoncurrent

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-31
Value8261148863963830511697697731751
Percentage of MarketableSecuritiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan

us-gaap:RestructuringReserve

us-gaap:EmployeeSeverance, jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-01
Value158164180187193194200206213229245251355380
Percentage of RestructuringReserve100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherRestructuring, jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-01
Value7162515748233118384471
Percentage of RestructuringReserve4.49.813.98.03.624.711.515.08.516.61.61.62.00.3

us-gaap:RestructuringPlan

jnj:MedicalDevices



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-01
Value165180205202200242223237231267249255362381
Percentage of RestructuringReserve104.4109.8113.9108.0103.6124.7111.5115.0108.5116.6101.6101.6102.0100.3

us-gaap:ShortTermBorrowings



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value219012022299171917082796177326782696390684917209535546843443170831167004567752224045363821153819394948525359533945294676542360406439665853265046857576176318
Percentage of ShortTermBorrowings100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueByMeasurementBasis

us-gaap:CarryingReportedAmountFairValueDisclosure



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value219022991719170817732678269684917209535534431708311656775222404521153819394953595339
Percentage of ShortTermBorrowings100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EstimateOfFairValueFairValueDisclosure



Period End2020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value223423491739170817732678269684917209535534431708311656775222404521153819394953595339
Percentage of ShortTermBorrowings102.0102.2101.2100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:TreasuryStockShares



Period End2020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-282007-12-30
Value487487488477464457436437437437434434424413397382368364352350343336315297292299299305316341357369374395387379381381365350279
Percentage of TreasuryStockShares100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Line plots across dimensions of each concept

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical


us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments


us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems


us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments


us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity


us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType


us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType


us-gaap:Goodwill us-gaap:StatementBusinessSegments


us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass


us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable


us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents